多田 篤司 (タダ アツシ)

北海道大学病院 内科講師

研究者基本情報

■ 学位
  • 医学博士, 北海道大学, 2022年03月
  • 学士, 北海道大学, 2013年03月
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 10962904
ORCID IDJ-Global ID■ 研究キーワード・分野
研究キーワード
  • 心不全
  • 血行動態
  • 運動負荷試験
  • 心臓サルコイドーシス
  • 心臓アミロイドーシス
研究分野
  • ライフサイエンス, 循環器内科学, 心不全、虚血性心疾患、心筋症
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2025年07月 - 現在
    北海道大学病院, 循環器内科, 講師, 日本国
  • 2025年04月 - 2025年06月
    北海道大学病院, 循環器内科, 助教
  • 2024年04月 - 2025年03月
    米国Mayo Clinic, Department of Cardiovascular Medicine, Research Fellow, アメリカ合衆国
  • 2023年04月 - 2025年03月
    北海道大学大学院医学研究院, 循環病態内科学, 客員研究員
  • 2023年04月 - 2024年03月
    米国Mayo Clinic, Department of Cardiovascular Medicine, Visiting Research Fellow
  • 2022年04月 - 2023年03月
    北海道大学, 循環器内科, 助教, 日本国
  • 2019年04月 - 2022年03月
    北海道大学大学院 医学研究院, 循環病態内科学, 大学院生
  • 2017年04月 - 2019年03月
    苫小牧市立病院, 循環器内科
  • 2015年04月 - 2017年03月
    北見赤十字病院, 循環器内科
  • 2013年04月 - 2015年03月
    市立函館病院, 初期研修医
  • 2013年03月
    北海道大学, 医学部医学科, 日本国
委員歴
  • 2021年04月 - 2023年03月
    日本循環器学会 急性および慢性心筋炎の診断・治療に関するガイドライン作成班, 協力員, 学協会
  • 2020年04月 - 2022年03月
    日本循環器学会 非心臓手術における合併心疾患の評価と管理に関するガイドライン作成班, 協力員, 学協会

研究活動情報

■ 受賞
  • 2026年03月, 北海道大学医学部同窓会, 令和7年度フラテ研究奨励賞
    多田篤司
  • 2026年02月, 北海道大学大学院・医学研究院, 優秀論文賞
    多田 篤司
  • 2023年03月, 北海道大学大学院医学院・医学部医学科, 第42回高桑榮松奨学基金奨学金
    多田篤司
  • 2022年10月, Young Investigator’s Award 優秀賞 第26 回日本心不全学会学術集会
    多田篤司
  • 2021年08月, 北海道大学大学院医学院・医学部医学科, 第17回音羽博次奨学基金
    多田篤司
  • 2020年, 公益財団法人伊藤医薬学術交流財団, 第26回海外交流助成賞
    多田篤司
■ 論文
  • Exercise stress echocardiography for diagnosis of heart failure with preserved ejection fraction: a multicentre study.
    Tomonari Harada; Yogesh N V Reddy; Hidemi Sorimachi; Jwan A Naser; Sho Kazui; Atsushi Tada; Shunichi Doi; Tatsuro Ibe; Rickey E Carter; Ryan T Demmer; Kazuki Kagami; Lynn Manhaeghe; Shane Nanayakkara; Frederik H Verbrugge; David M Kaye; Patricia A Pellikka; Masaru Obokata; Barry A Borlaug
    European heart journal, 2026年09月10日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND AND AIMS: Exercise stress echocardiography is recommended as an alternative to invasive testing for diagnosing heart failure with preserved ejection fraction (HFpEF), but an evidence-based operational framework guiding its application is lacking. METHODS: Patients with chronic unexplained dyspnoea underwent invasive haemodynamic exercise testing with simultaneous echocardiography to test the hypotheses that (i) the current diagnostic algorithms (H2FPEF, HFA-PEFF, and HFpEF-ABA scores) could be enhanced when combined with exercise echocardiography; and (ii) incorporating resting left atrial (LA) compliance (LA reservoir strain divided by E/e') could further improve diagnostic triage, using separate cut points optimizing sensitivity and specificity. Findings were then validated in an international multicentre cohort. RESULTS: Of 482 patients, HFpEF was present in 386 and non-cardiac dyspnoea in 96. Sensitivity to detect HFpEF was only 55%-60% and accuracy 61%-67% using individual diagnostic scores with currently recommended exercise echocardiography. Addition of abnormal resting LA compliance to exercise echocardiography increased sensitivity to 84%-85% but increased the false-positive rate to 31%-43%. Applying separate cut points that optimize specificity and sensitivity (either exercise E/e' ≥ 13.8 or resting LA compliance ≤1.6% to rule-in HFpEF; both exercise E/e' < 7.2 and resting LA compliance >4.4% to rule-out HFpEF, remaining patients indeterminate who require invasive testing) improved sensitivity to 95%-99% among definitively classified patients and reduced the number of patients that require invasive exercise testing from ∼60% to ∼30%. Findings were replicated in a multicentre, international validation cohort of patients undergoing rest-exercise echocardiography and invasive exercise testing. CONCLUSIONS: Currently used non-invasive approaches to HFpEF diagnosis have inadequate sensitivity, indicating that exercise echocardiography cannot supplant invasive testing. Addition of LA strain imaging with optimized rule-in or rule-out values improves diagnostic triage by expanding non-invasive rule-in/rule-out classifications while identifying patients who still require invasive testing in the evaluation of HFpEF.
  • Autoimmune myocarditis associated with subcutaneous panniculitis-like T-cell lymphoma without HAVCR2 germline mutation
    Rui Katano; Souichi Shiratori; Satonori Tsuneta; Atsushi Tada
    European Heart Journal - Case Reports, 2026年08月27日, [査読有り], [責任著者]
    研究論文(学術雑誌)
  • Prognostic Value of New Proposed Criteria for Atrial Cardiomyopathy in Patients With Heart Failure.
    Hiroki Uehara; Makoto Kambayashi; Toshiyuki Nagai; Shota Saito; Kosuke Nakamura; Motoki Nakao; Yoshifumi Mizuguchi; Isao Yokota; Taro Koya; Atsushi Tada; Suguru Ishizaka; Fusako George; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Yutaka Wakamatsu; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    JACC. Advances, 103182, 103182, 2026年08月14日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Atrial function plays a crucial role in patients with heart failure (HF). Recently, criteria for atrial cardiomyopathy (AtCM) have been proposed based on both electrical and mechanical atrial dysfunction. However, it is unclear whether AtCM defined by the proposed criteria can stratify the risk of adverse events in patients with HF. OBJECTIVES: The authors sought to investigate the association between AtCM and clinical outcomes. METHODS: Between January 2020 and June 2025, 2,046 symptomatic patients with chronic HF from a multicenter registry were prospectively enrolled. Patients who exhibited baseline electrical and mechanical atrial dysfunction on electrocardiography and echocardiography were diagnosed with AtCM. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: During a median follow-up period of 727 days (IQR: 518-1,119), the primary outcome occurred in 427 patients. The incidence of the primary outcome was higher in patients with AtCM than in those without AtCM (P < 0.001). Multivariable regression analyses showed that the presence of AtCM was associated with a higher risk of the primary outcome after adjustment for prognostic covariates, including atrial fibrillation (HR: 1.31; 95% CI: 1.00-1.70). The coexistence of electrical and mechanical atrial dysfunction showed the highest risk of adverse events. CONCLUSIONS: AtCM defined by the proposed criteria identified patients with HF at increased risk of adverse events. Combined electrical and mechanical atrial dysfunction characterized a subgroup with markedly elevated risk, underscoring the clinical relevance of integrating both domains when diagnosing AtCM. (Development of a flail evaluation application based on deep learning; UMIN000043390).
  • Erythropoietin Resistance and Outcomes According to SGLT2 Inhibitor Use in Anemic Patients With Heart Failure.
    Toshifumi Tamura; Toshiyuki Nagai; Motoki Nakao; Shu Tahara; Yoshifumi Mizuguchi; Taro Koya; Atsushi Tada; Fusako George; Isao Yokota; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Yutaka Wakamatsu; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    Journal of cardiac failure, 2026年08月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Case report: fulminant myocarditis with biopsy-proven eosinophilic infiltration and burned-out myocardial pathology at autopsy
    Rui Katano; Atsushi Tada; Hirokazu Sugino; Toshiyuki Nagai; Toshihisa Anzai
    European Heart Journal - Case Reports, 2026年07月31日, [査読有り], [責任著者]
    研究論文(学術雑誌)
  • Clinical Implications of Resting Metabolic Rate in Heart Failure with Preserved Ejection Fraction.
    Tatsuro Ibe; Jwan A Naser; Tomonari Harada; Atsushi Tada; Shunichi Doi; Yogesh N V Reddy; Vojtech Melenovsky; Michael D Jensen; Barry A Borlaug
    Journal of cardiac failure, 2026年07月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is causally related to obesity. Adipose tissue accumulates when energy intake exceeds expenditure. Resting metabolic rate (RMR) is a key determinant of energy expenditure, but has not been evaluated in HFpEF. METHODS: Patients with HFpEF undergoing invasive hemodynamic exercise testing were categorized into lower- or higher-than-expected measured RMR groups based on the difference between directly measured RMR, calculated using the Weir equation (indirect calorimetry), and predicted RMR, estimated using the Mifflin-St Jeor equation. RESULTS: Of 472 patients with HFpEF, 212 had lower-than-expected RMR and 260 had higher-than-expected RMR. Compared with patients with lower-than-expected RMR, those with higher-than-expected RMR were older (69±10 vs. 65±11 years, P<0.001), more frequently women (66.2% vs. 43.9%, P<0.001), and less likely to be obese (53.9% vs. 75.0%, P<0.001). At rest, patients with higher-than-expected RMR displayed hemodynamic adaptations consistent with increased metabolic demand, including left ventricular dilatation, higher stroke work and stroke volume index, and vasodilation. However, during exercise, patients with higher-than-expected RMR displayed blunted augmentation in cardiac performance and inadequate vasodilation, indicating impaired cardiovascular reserve. Over a median follow-up of 4.6 (2.2, 6.4) years, patients with higher-than-expected RMR had greater risk of cardiovascular death or HF hospitalization compared with those with lower-than-expected RMR (HR 2.66 [95% CI 1.43-4.94], P=0.002). CONCLUSIONS: Patients with HFpEF and lower-than-expected RMR have greater prevalence of obesity, and those with higher-than-expected RMR display circulatory adaptations to heightened metabolic demand at rest, which are coupled with blunted reserve capacity with exercise, and increased risk for adverse clinical outcomes. Further studies are warranted to elucidate the underlying mechanisms by which RMR contributes to the pathophysiology of HFpEF and to clarify its potential utility in therapeutic strategies.
  • Temporal Changes in Guideline-Directed Medical Therapy Score and Clinical Outcomes in Patients with Heart Failure.
    Toshifumi Tamura; Toshiyuki Nagai; Motoki Nakao; Yoshifumi Mizuguchi; Taro Koya; Atsushi Tada; Fusako George; Isao Yokota; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Yutaka Wakamatsu; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    European heart journal. Quality of care & clinical outcomes, 2026年06月19日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Optimisation of guideline-directed medical therapy (GDMT) is a cornerstone of management in heart failure (HF). The GDMT scoring system was developed to quantify both the use and intensification of GDMT. This study investigated the longitudinal changes in the GDMT score and its association with clinical outcomes in contemporary practice. METHODS AND RESULTS: This multicentre prospective cohort study included 680 patients with chronic HF with reduced ejection fraction. The patients were classified into the up-titration (n = 282) and no up-titration (n = 398) groups according to changes in the GDMT score over 9 months. The GDMT score incorporated the use and dose of guideline-recommended drugs including quadruple therapy, ivabradine, and vericiguat. The primary outcome was a composite of all-cause death and hospitalisation for worsening HF. Inverse probability of treatment weighting was used to adjust for baseline differences. Up-titration rates at 9 months were 31.8% for renin-angiotensin system blockers, 28.2% for β-blockers, 10.6% for mineralocorticoid receptor antagonists, and 11.9% for sodium-glucose cotransporter 2 inhibitors. Up-titration was independently associated with baseline GDMT score, age, left ventricular ejection fraction, blood pressure, and renal function. Furthermore, up-titration was associated with a lower incidence of the primary outcome than no up-titration (adjusted HR, 0.65; 95% CI, 0.43-0.98). CONCLUSION: In this contemporary chronic HF cohort, the GDMT score incorporating guideline-recommended drugs revealed suboptimal implementation and intensification of GDMT over 9 months. Greater increases in GDMT score were associated with improved clinical outcomes, supporting the clinical relevance of longitudinal GDMT optimisation.
  • Steroid-Refractory Fulminant Lymphocytic Myocarditis Successfully Treated with Tacrolimus Guided by Serial Cardiac Magnetic Resonance Imaging
    Yu Agata; Atsushi Tada; Satonori Tsuneta; Noriyuki Otsuka; Utano Tomaru; Rui Katano; Kenta Otsuka; Yutaro Yasui; Toshiyuki Nagai; Kohsuke Kudo; Shinya Tanaka; Toshihisa Anzai
    CJC Open, Elsevier BV, 2026年05月, [査読有り]
    研究論文(学術雑誌)
  • Kidney Dysfunction and Pulmonary Vascular Disease in Heart Failure with preserved Ejection Fraction.
    Matthew B Amdahl; Jwan A Naser; Atsushi Tada; Shunichi Doi; Tomonari Harada; Tatsuro Ibe; Jeffrey M Testani; Vojtech Melenovsky; Yogesh N V Reddy; Barry A Borlaug
    European journal of heart failure, 2026年04月27日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Chronic kidney disease (CKD) is common in patients with heart failure (HF) with preserved ejection fraction (HFpEF), and its presence is associated with more severe echocardiographic abnormalities and poorer outcomes through unclear mechanisms. CKD-associated endothelial dysfunction, inflammation, and activation of profibrotic pathways could worsen pulmonary vascular disease (PVD) in HFpEF, but such relationships have not been explored. METHODS: Consecutively evaluated patients with HFpEF undergoing invasive hemodynamic cardiopulmonary exercise testing were stratified by baseline kidney function to characterize potential differences in pulmonary vascular loading, hemodynamics, cardiopulmonary reserve, and outcomes based upon the presence and severity of kidney dysfunction. RESULTS: Of 925 patients with HFpEF, 319 (34.5%) had eGFR < 60 ml/min/1.73 m2. Patients with more severe kidney dysfunction were older and more likely to have diabetes, atrial fibrillation, and hypertension.. At rest, reduced kidney function was associated with lower hemoglobin, higher biventricular filling pressures, and lower cardiac output, but the severity of kidney dysfunction was most conspicuously associated with worsening PVD, evidenced by increasing pulmonary arterial (PA) pressures due to marked increases in pulmonary vascular resistance (PVR) as kidney dysfunction progressed (median [IQR] 1.3 [0.86, 1.88] to 2.8 [2.0, 3.8] WU from eGFR ≥ 90 to eGFR < 30, p<0.001), along with progressively lower PA compliance (PAC, 4.7 [3.6, 5.8] to 2.2 [1.8, 3.4] ml/mmHg from eGFR ≥ 90 to eGFR < 30, p<0.001). With exercise, differences in the severity of PVD became even more striking, with more severe elevation in PA pressures and PVR, and lower PA compliance, leading to lower transmural left-sided distending pressures, with no difference in exertional PA wedge pressure. Patients with worse kidney dysfunction displayed the most dramatic cardiac output limitations with exercise, which along with more severe anemia and markedly reduced O2 delivery, caused marked impairment in aerobic capacity. Worsening kidney function was associated with a striking gradient of increased risk of a composite of all-cause death and HF hospitalization [ranging from HR 2.38 (95% CI 1.01-5.59) for eGFR 60-90 to HR 16.77 (95% CI 6.65-42.28) for eGFR < 30 (vs. reference eGFR ≥ 90)]. CONCLUSIONS: Kidney dysfunction in patients with HFpEF is characterized by more severe pulmonary vascular disease at rest and with exercise, leading to reduced cardiac output reserve, impaired exercise capacity, and increased risk for adverse events. Further study is warranted to better understand causal relationships between CKD and PVD, and determine whether novel therapies to improve kidney function might target these impairments to improve clinical status.
  • Prognostic Value of Mid-Range QRS Duration in Patients With Heart Failure With Reduced Ejection Fraction.
    Shota Saito; Taro Temma; Toshiyuki Nagai; Motoki Nakao; Isao Yokota; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Yuki Takahashi; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Junichi Matsumoto; Masashige Takahashi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihiro Shimizu; Toshihisa Anzai
    Circulation journal : official journal of the Japanese Circulation Society, 2026年04月25日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Prolonged QRS is an established marker of adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the prognostic significance of modest QRS prolongation (120-149 ms; mid-range QRS) remains unclear, especially in patients without cardiac implantable electronic devices (CIEDs). This study assessed the natural prognosis associated with mid-range QRS compared with narrow QRS (<120 ms) in a recent Asian cohort of patients with HFrEF. METHODS AND RESULTS: We analyzed patients with HFrEF from the Epidemiological Multicenter Study for Tailored Treatment in Heart Failure (ELMSTAT-HF; January 2020-October 2023). QRS was measured from 12-lead electrocardiograms. Patients with wide QRS (≥150 ms) or CIEDs were excluded. The primary outcome was a composite of all-cause mortality and heart failure hospitalizations. Multivariable Cox models adjusted for the MAGGIC risk score and log-transformed N-terminal pro B-type natriuretic peptide were used. Among 415 patients, 328 had narrow QRS and 87 had mid-range QRS. Over a median follow-up of 547 days, the primary outcome occurred more frequently in the mid-range QRS group (34.5% vs. 12.5%; P<0.001). Mid-range QRS remained independently associated with adverse outcomes (hazard ratio 3.12; 95% confidence interval 1.91-5.11), consistent across non-left bundle branch block (LBBB) and LBBB subgroups. CONCLUSIONS: Mid-range QRS is an independent predictor of adverse outcomes in HFrEF, even in the absence of LBBB.
  • Association of Lipid Core Burden Index With Early Progression of Cardiac Allograft Vasculopathy in Patients After Heart Transplantation.
    Kenta Otsuka; Sakae Takenaka; Toshiyuki Nagai; Takuma Sato; Takao Konishi; Atsushi Tada; Takeshi Hamaya; Yuki Mori; Akinori Takahashi; Sou Sasaki; Kento Tamano; Toshifumi Tamura; Sho Kazui; Yutaro Yasui; Yuta Kobayashi; Taro Temma; Kiwamu Kamiya; Satoru Wakasa; Toshihisa Anzai
    Circulation journal : official journal of the Japanese Circulation Society, 2026年04月14日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The association of the lipid-core burden index (LCBI), measured using near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), with early progression of cardiac allograft vasculopathy remains unclear. METHODS AND RESULTS: We prospectively examined 12 consecutive heart transplant recipients who underwent NIRS-IVUS and IVUS. Patients were stratified according to the median maximum LCBI in a 4-mm segment (maxLCBI4 mm) of 223 at 1 month. The magnitude of maximal intimal thickness (MIT) progression was greater in the higher maxLCBI4 mmgroup. CONCLUSIONS: Patients with a higher maxLCBI4 mmat baseline exhibited greater MIT progression during the first post-transplant year.
  • Multimodality imaging of the right ventricular outflow tract haemangioma requiring pulmonary valve replacement
    Rui Katano; Satonori Tsuneta; Satoru Wakasa; Atsushi Tada
    European Heart Journal - Case Reports, 2026年03月02日, [査読有り], [責任著者]
    研究論文(学術雑誌)
  • Progression From Exercise-Induced to Resting Left Atrial Hypertension in HFpEF: Impact of Reduced Atriopulmonary Compliance.
    Atsushi Tada; Jwan A Naser; Shunichi Doi; Tomonari Harada; Tatsuro Ibe; Sho Kazui; Yogesh N V Reddy; Margaret M Redfield; Barry A Borlaug
    JACC. Heart failure, 102947, 102947, 2026年02月10日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Approximately one-third of patients with heart failure and preserved ejection fraction (HFpEF) have normal pulmonary capillary wedge pressure (PCWP) at rest, with left atrial (LA) hypertension that is induced only during exercise (exercise-induced left atrial hypertension [EILAH]). EILAH may represent a discrete HFpEF phenotype or an earlier stage of HFpEF that progresses to resting left atrial hypertension (RELAH) over time. OBJECTIVES: The authors investigated the clinical course of HFpEF patients with EILAH who underwent repeat invasive hemodynamic evaluation. METHODS: This observational study investigated the natural history of EILAH and evaluated patients who underwent multiple invasive hemodynamic studies to assess for progression from EILAH to RELAH and then identify pathophysiological correlates of progression. Consecutively evaluated patients with HFpEF and EILAH (PCWP <15 mm Hg at rest and ≥25 mm Hg during exercise) who underwent repeat invasive hemodynamic testing were identified. RESULTS: Of 659 patients with EILAH, 84 underwent repeat invasive hemodynamic evaluations over a median follow-up of 1.81 years (Q1-Q3: 0.48-3.40 years). Of this group, 33 (39%) patients changed to RELAH (PCWP ≥15 mm Hg at rest) and 51 (61%) did not. Patients with a change to RELAH had a greater duration between their index and repeat catheterizations (2.68 years [Q1-Q3: 1.74-3.97 years] vs 0.99 years [Q1-Q3: 0.44-2.16 years]; P = 0.001), and they experienced greater increases in N-terminal pro-B-type natriuretic peptide (interaction P = 0.036), more severe worsening in left ventricular ejection fraction (P < 0.001), right ventricular free wall longitudinal strain (P = 0.003), and more worsening tricuspid regurgitation (+15% vs +2%; P = 0.025) compared with patients who did not transition to RELAH. Of characteristics at the index evaluation, a history of atrial fibrillation (OR: 4.57 [95% CI: 1.63-12.8]), lower LA compliance (OR: 0.47 [95% CI: 0.22-0.99]), and lower pulmonary artery compliance (OR: 0.48 [95% CI: 0.25-0.93]) were independently associated with the transition to RELAH after adjusting for follow-up duration. CONCLUSIONS: Many patients with HFpEF who first present with EILAH transition to RELAH, thus suggesting that EILAH may represent an earlier stage of HFpEF. A history of atrial fibrillation, impaired LA compliance, and reduced pulmonary artery compliance are associated with progression to RELAH. These findings call for further studies of interventions enhancing atriopulmonary compliance in early-stage HFpEF.
  • Rapidly Progressive Pulmonary Hypertension: Importance of Vascular Disease Distribution
    Atsushi Tada; Ahmed U. Fayyaz; Yogesh N.V. Reddy; Margaret M. Redfield; Barry A. Borlaug
    Circulation, 2026年01月27日, [査読有り], [筆頭著者]
    研究論文(学術雑誌)
  • Prognostic value of preprocedural pulmonary artery to ascending aorta ratio on non-contrast computed tomography in patients undergoing mitral transcatheter edge-to-edge repair.
    Hiroki Uehara; Toshiyuki Nagai; So Sasaki; Kento Tamano; Toshifumi Tamura; Akinori Takahashi; Takeshi Hamaya; Yuki Mori; Yutaro Yasui; Sakae Takenaka; Satonori Tsuneta; Suguru Ishizaka; Yuta Kobayashi; Atsushi Tada; Taro Temma; Kiwamu Kamiya; Toshihisa Anzai
    Heart and vessels, 2026年01月21日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Prognostic value of 18F-fluorodeoxyglucose positron emission tomography one month after initiation of prednisolone therapy in patients with cardiac sarcoidosis.
    Toshifumi Tamura; Sakae Takenaka; Toshiyuki Nagai; Satonori Tsuneta; Takeshi Hamaya; Kenji Hirata; Yoshiya Kato; Hirokazu Komoriyama; Yuta Kobayashi; Atsushi Tada; Sho Kazui; Yutaro Yasui; Akinori Takahashi; Kiwamu Kamiya; Taro Temma; Takahiro Sato; Ichizo Tsujino; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
    International journal of cardiology, 134181, 134181, 2026年01月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Current guidelines for cardiac sarcoidosis (CS) recommend maintaining the initial maximal dose of prednisolone (PSL) for one month after initiation; however, the prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) performed at this time point remains unclear. We sought to investigate whether FDG-PET performed at one month after the initiation of PSL is associated with adverse events in patients with CS. METHODS: We examined 109 consecutive CS patients who underwent FDG-PET at diagnosis and one month after initiating PSL between January 2010 and January 2025 in a university hospital. The change in maximum standardized uptake value (SUVmax) from baseline to one month was calculated. Responder was defined as those with an SUVmax reduction ≥25%, while non-responder had a reduction <25% or any increase. The primary outcome was a composite of aborted sudden cardiac death, sustained ventricular tachycardia, hospitalization of worsening heart failure, and all-cause death. RESULTS: Of the 109 patients, 83 were classified as responder and 26 as non-responder. Over a median follow-up of 4.9 years (interquartile range, 2.3-8.2), the primary outcome occurred in 37 patients. Non-responder had a significantly higher risk of the primary outcome, and this association persisted after sequential adjustment for established prognostic covariates. CONCLUSIONS: An inadequate reduction in SUVmax on FDG-PET performed one month after PSL initiation was independently associated with adverse clinical events in patients with CS. These findings suggest that non-responder represents a clinical challenge and even very early follow-up FDG-PET may provide prognostic insights.
  • Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.
    Tomonari Harada; Hidemi Sorimachi; Masaru Obokata; Jwan A Naser; Tatsuro Ibe; Atsushi Tada; Shunichi Doi; Sho Kazui; Tsukasa Murakami; Kazuki Kagami; Yogesh N V Reddy; William R Miranda; Lynn Manhaeghe; Shane Nanayakkara; Carolina Janssen-Telders; M Louis Handoko; Frederik H Verbrugge; David M Kaye; Barry A Borlaug
    Journal of the American College of Cardiology, 2026年01月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Echocardiographic grading of left ventricular diastolic function is recommended to guide diagnostic evaluation of heart failure with preserved ejection fraction (HFpEF). A new algorithm for diastolic function interpretation has been proposed, but it has not yet been systematically evaluated in HFpEF. OBJECTIVES: The purpose of this study was to determine the false-negative rate of the 2025 American Society of Echocardiography (ASE) algorithm among invasively confirmed ambulatory HFpEF, assess temporal changes in diastolic grades between decompensated and recompensated hospitalized HFpEF, and, secondarily, to compare diagnostic discrimination with existing HFpEF algorithms and prognostic associations. METHODS: Echocardiography was performed in 2 HFpEF cohorts: 1) ambulatory, compensated patients undergoing invasive hemodynamic exercise testing as part of a prospective cohort study, with an external validation cohort; and 2) hospitalized/decompensated patients both acutely and following recompensation. For secondary analyses, we included noncardiac dyspnea controls and compared performance with existing algorithms. RESULTS: In the ambulatory/compensated HFpEF cohort, 248 of 756 (32.8%) were graded normal, 263 of 756 (34.8%) had Grade 1 diastolic dysfunction, 219 of 756 (30.0%) had Grades 2 to 3, and 26 of 756 (3.4%) were indeterminate. Among those labeled normal or Grade 1, >60% had resting pulmonary artery wedge pressure ≥15 mm Hg at catheterization. In decompensated HFpEF, 22 of 88 (25.0%) showed normal or Grade 1, and this proportion increased to 45 of 88 (51.1%) after recompensation. In HFpEF with Grade 1 undergoing simultaneous hemodynamic exercise testing with stress imaging, only 11 of 116 (9.5%) met the ASE-recommended stress criteria, resulting in a 90.5% false-negative rate. Similar findings were observed in the external validation cohort. The 2025 ASE algorithm poorly discriminated HFpEF from noncardiac dyspnea (AUC: 0.61). Patients with HFpEF labeled as normal or Grade 1 had 5-fold higher risk for all-cause death or heart failure hospitalization compared with controls (HR: 5.37; 95% CI: 1.27-22.6). CONCLUSIONS: Among patients with invasively proven HFpEF, the 2025 ASE algorithm frequently assigns normal or low diastolic grades, and the recommended stress criteria detect only a minority of cases. Although echocardiography remains essential to guide HFpEF evaluation, current algorithms proposed have inadequate sensitivity. Diastolic function grades must be interpreted in the context of pretest probability and HFpEF-specific, evidence-based frameworks, rather than used in isolation to exclude disease.
  • Intermittent Mechanical Aortic Valve Sticking Due to Pannus Formation Complicated by Coronary Embolism and Cardiac Arrest
    Yu Agata; Atsushi Tada; Hiroshi Sugiki; Koji Sato; Rui Katano; Kenta Otsuka; Yutaro Yasui; Suguru Ishizaka; Toshiyuki Nagai; Satoru Wakasa; Toshihisa Anzai
    Canadian Journal of Cardiology, 2026年01月, [査読有り], [責任著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Cardiac Dysfunction, Exercise Reserve, and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With an Implanted Pacemaker
    KAZUNORI OMOTE; ATSUSHI TADA; TOMONARI HARADA; HIDEMI SORIMACHI; MASARU OBOKATA; YOGESH N.V. REDDY; BARRY A. BORLAUG
    Journal of Cardiac Failure, 31, 11, 1684, 1694, Elsevier BV, 2025年11月, [査読有り]
    研究論文(学術雑誌)
  • Pulmonary arterial wedge pressure exceeding left atrial pressure: clinical implications.
    Atsushi Tada; Kazunori Omote; Ahmed U Fayyaz; Trevor J Simard; William R Miranda; Jwan A Naser; Yogesh N V Reddy; Margaret M Redfield; Barry A Borlaug
    European heart journal, 46, 40, 4123, 4126, 2025年10月22日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌)
  • Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction.
    Jwan A Naser; Tomonari Harada; Atsushi Tada; Martin Chun Kit Wong; Serena J Rahme; Austin M Kennedy; Yue Yu; Yogesh N V Reddy; Sorin V Pislaru; Barry A Borlaug
    Journal of the American College of Cardiology, 2025年10月13日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Secondary tricuspid regurgitation (STR) in heart failure with preserved ejection fraction (HFpEF) is linked to more advanced stages with pulmonary vascular disease (PVD), but it may also develop at earlier stages of HFpEF, such as those with isolated exercise-induced congestion. OBJECTIVE: In this study, we sought to evaluate the prevalence, distribution, and prognostic significance of STR mechanisms across the spectrum of HFpEF. METHODS: Cardiac structure, function, hemodynamics, and clinical outcomes were compared among patients with HFpEF phenotypes categorized according to the presence of PVD (pulmonary vascular resistance >2 WU), and elevation in filling pressure at rest vs provocation (leg-elevation or exercise), as well as according to the presence of atrial or ventricular STR (A-STR, V-STR). RESULTS: Of 1,091 patients (median age 65 years, 60.3% women), 669 (61.3%) had HFpEF (20.2% exercise HFpEF - PVD, 38.6% rest HFpEF - PVD, 15.5% exercise HFpEF + PVD, 25.7% rest HFpEF + PVD). Moderate or severe STR was present in 17.4% overall, but increased with PVD (6.7%, 11.6%, 18.3%, and 33.7%, respectively), although moderate or severe STR was still more common in exercise-only HFpEF vs noncardiac dyspnea patients (11.7% vs 6.5%; P = 0.047). Most STR (69%) fulfilled criteria for V-STR, but those individuals had similar atrial fibrillation prevalence and greater atrial remodeling compared with A-STR. V-STR was independently associated with composite of death or heart failure (HF) hospitalization (multivariable HR: 1.70; 95% CI: 1.10-2.65) as well as death and HF hospitalizations each alone, whereas A-STR was associated with increased risk of HF hospitalizations (multivariable Fine-Gray HR: 2.21; 95% CI: 1.12-4.37). CONCLUSIONS: STR in HFpEF is associated with PVD and less strongly with higher resting filling pressure. Although V-STR is the more common phenotype of STR in HFpEF, these patients also have substantial atrial myopathy, suggesting a mixed mechanism. TR was more prevalent in exercise HFpEF and exercise pulmonary hypertension than with noncardiac dyspnea; with none in the latter group having moderate-severe or severe TR, highlighting the importance of exercise hemodynamics. V-STR conferred excess mortality and HF hospitalizations, but A-STR conferred only excess HF hospitalizations.
  • 北海道大学病院における心臓移植の検討
    杉木 宏司; 新宮 康栄; 斎藤 慈円; 南田 大朗; 佐藤 公治; 加藤 信康; 大岡 智学; 若狭 哲; 多田 篤司; 竹中 秀; 石坂 傑; 永井 利幸; 安斉 俊久; 櫛引 勝年; 有賀 知里
    移植, 60, 317, 317, (一社)日本移植学会, 2025年10月
    日本語
  • Dynamic tricuspid regurgitation in heart failure with preserved ejection fraction.
    Tomonari Harada; Yogesh N V Reddy; Hidemi Sorimachi; Masaru Obokata; Jwan A Naser; Atsushi Tada; Shunichi Doi; Tatsuro Ibe; Mackram F Eleid; Sorin V Pislaru; Rebecca T Hahn; Barry A Borlaug
    European journal of heart failure, 2025年09月22日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: The pathophysiology of tricuspid regurgitation (TR) during exercise in heart failure with preserved ejection fraction (HFpEF) is not well understood. METHODS AND RESULTS: We investigated dynamic changes in TR severity during exercise in patients with HFpEF and associated relationships with haemodynamics, cardiopulmonary reserve, and prognosis using invasive haemodynamic exercise testing with simultaneous echocardiography and expired gas analysis. Among 169 patients with HFpEF (91 no TR, 44 mild TR, 34 ≥ moderate TR), older age and atrial fibrillation were more common in patients with greater TR severity. Right heart remodelling and dysfunction were more frequently observed with greater TR severity, particularly in the right atrium, along with stepwise increases in right atrial (RA) pressure and interventricular septal flattening, and decreases in cardiac output (CO). During exercise, TR severity frequently worsened, and over half of the patients with moderate TR at rest displayed severe TR during exercise, accompanied by profound RA dilatation, reduced RA reservoir strain, increased septal flattening, and more severely impaired CO reserve. Abnormalities in tricuspid annular motion and ventricular interaction were amplified by exercise with greater TR, but exercise pulmonary vascular pressures did not differ across groups. Patients with ≥ moderate TR during exercise displayed higher event rates (hazard ratio 2.85, 95% confidence interval 1.18-6.85), but patients with mild TR had similar prognosis as those without TR in adjusted models. CONCLUSIONS: Tricuspid regurgitation in HFpEF is related to advanced RA myopathy and often worsens during exercise leading to dynamic right-sided heart failure, exaggerated ventricular interaction, impaired CO reserve, and increased risk for adverse outcomes. These data emphasize the clinical importance of exercise evaluation and call for further study of novel treatments in those with significant resting and provocable TR.
  • Utility of HFpEF Diagnostic Scores to Stratify Cardiac Reserve Among Patients With Dyspnea.
    Tatsuro Ibe; Yogesh N V Reddy; Tomonari Harada; Shunichi Doi; Atsushi Tada; Jwan A Naser; Ryan T Demmer; Barry A Borlaug
    JACC. Heart failure, 13, 10, 102526, 102526, 2025年08月05日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The heart failure with preserved ejection fraction (HFpEF) scores were initially developed to facilitate diagnosis of HFpEF in patients with dyspnea. Whether these diagnostic scores also relate to severity of cardiopulmonary reserve limitations across the broad range of patients with dyspnea, with or without confirmed HFpEF, remains unclear. OBJECTIVES: The purpose of this study was to investigate the association between HFpEF scores and disease severity in patients with dyspnea. METHODS: Patients undergoing invasive cardiopulmonary exercise testing for unexplained dyspnea were studied. Cardiac structure, function, and cardiopulmonary reserve were compared based on H2FPEF, HFA-PEFF, and HFpEF-ABA scores. RESULTS: A total of 1,130 subjects were included in this study, of whom 902 had HFpEF and 228 had noncardiac dyspnea. Patients were categorized by HFpEF-ABA score into low (probability <25%, n = 91), intermediate (probability 25%-80%, n = 559), and high HFpEF probabilities (probability >80%, n = 480). Patients with high HFpEF-ABA score exhibited more severe structural and functional abnormalities characteristic of HFpEF, across virtually all morphological and functional indices, as well as hemodynamic and cardiopulmonary indices. Similar findings were observed using the H2FPEF and HFA-PEFF scores, and when analyses were restricted to those with HFpEF or to those with noncardiac dyspnea. CONCLUSIONS: The HFpEF scores stratify the extent of cardiac dysfunction, hemodynamic severity, and functional limitation in a broad cohort of individuals with chronic dyspnea, across the overall cohort and within individuals with or without HFpEF. These data indicate that HFpEF probability scores may also be used as markers of disease severity and preclinical HFpEF.
  • Clinical Phenotyping and Treatment Response in Patients With Chronic Heart Failure.
    Daishiro Tatsuta; Motoki Nakao; Toshiyuki Nagai; Yoshifumi Mizuguchi; Isao Yokota; Taro Koya; Atsushi Tada; Suguru Ishizaka; Fusako George; Yoshiya Kato; Shogo Imagawa; Ko Motoi; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Masaharu Machida; Hiroshi Okamoto; Takahiko Saito; Toshihisa Anzai
    JACC. Advances, 4, 8, 101972, 101972, 2025年07月17日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: There are little data on clinically meaningful heart failure (HF) phenogroups, which are associated with treatment response across the wide spectrum of left ventricular (LV) ejection fraction. OBJECTIVES: The authors aimed to identify the phenotypes of patients with HF with different prognoses and responses to medical therapies. METHODS: We examined consecutive 2,301 chronic HF patients from the ELMSTAT-HF (EpidemioLogical Multicenter Study for Tailored Treatment in Heart Failure) registry, a prospective multicenter cohort in which 2,317 patients were enrolled between January 2020 and September 2024. Latent class analysis was performed using 99 clinical features. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: The analysis subclassified the patients into 8 phenogroups: group 1, characterized by younger age with obesity; 2, less structural abnormality and comorbidity; 3, younger age with LV dilation; 4, LV hypertrophy; 5, older age with small LV and diastolic dysfunction; 6, ischemic cardiomyopathy; 7, advanced LV remodeling and ventricular arrhythmias; and 8, atrial myopathy. During a median follow-up of 597 (IQR: 302-932) days, the incidence of the primary outcome significantly differed between the phenogroups (P < 0.001). In phenogroup 5, patients taking beta-blockers or sodium-glucose cotransporter 2 inhibitors had a significantly higher rate of hospitalization for worsening HF (HR: 2.20; 95% CI: 1.04-4.68; HR: 4.27; 95% CI: 2.02-9.05, respectively). CONCLUSIONS: We identified 8 phenogroups with distinct clinical outcomes in patients with HF. This phenotyping provides appropriate risk stratification and may aid clinical decision-making in patients with HF.
  • Physiologic Phenotyping of Responses to Exercise and Activity in Heart Failure.
    Gregory D Lewis; Atsushi Tada; Isabela Landsteiner; Barry A Borlaug
    Circulation research, 137, 2, 290, 315, 2025年07月07日, [査読有り], [招待有り], [国際誌]
    英語, 研究論文(学術雑誌), Subjective and objective limitations to exercise and activity are hallmarks of heart failure (HF), regardless of underlying ejection fraction (EF). These limitations relate to cardiovascular abnormalities involving the systolic and diastolic properties of the heart, venous, and arterial vasculature, as well as noncardiovascular abnormalities, including impairments in pulmonary function, autonomic regulation, anemia, metabolism, and changes in mitochondria and skeletal muscle. The contribution of these abnormalities varies between patients with HF with preserved EF and those with HF with reduced EF, but, even within each HF subtype, there is substantial individual patient pathophysiologic variability, which suggests a potentially important role for phenotyping based on exercise reserve responses to individualize treatment. In this article, we review the current understanding of exercise reserve limitation with a focus on specific organ systems involved, both in patients with HF with preserved EF and HF with reduced EF, and how these interact to lead to symptoms of exercise intolerance and objective limitations in submaximal and peak aerobic capacity across the spectrum of HF.
  • Prognostic significance of unintentional weight loss in heart failure with preserved ejection fraction.
    Tatsuro Ibe; Ryan T Demmer; Tomonari Harada; Shunichi Doi; Atsushi Tada; Jwan A Naser; Yogesh N V Reddy; Barry A Borlaug
    European journal of heart failure, 2025年06月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: While intentional weight loss achieved through cardiometabolic medications has been associated with robust salutary effects in heart failure (HF) with preserved ejection fraction (HFpEF), the clinical significance of unintentional weight loss in this setting remains unclear. METHODS AND RESULTS: This retrospective cohort study included 434 overweight or obese patients with invasively proven HFpEF (67 ± 11 years, 236 female), without weight-reducing therapies or known malignancy, who underwent invasive hemodynamic cardiopulmonary testing and long-term clinical follow-up. The annualized weight change from index to final evaluation for the tertiles was: -21.1 to -1.8 kg/year (tertile 1); -1.8 to 0 kg/year (tertile 2); and 0 to +17.0 kg/year (tertile 3). Patients in tertile 1 had subtle abnormalities in ventilatory control at baseline, but there were no other significant differences between groups across a vast array of haemodynamic and metabolic parameters, both at rest and during exercise. Baseline weight was directly correlated with right and left heart filling pressures (r = 0.23-0.34, p < 0.001), but annualized weight change showed no correlation with any baseline haemodynamic measurements (all p > 0.05). Over a median follow-up of 4.7 years (interquartile range 2.3-6.5), patients in tertile 1 had higher risk of all-cause death (hazard ratio [HR] 3.36, 95% confidence interval [CI] 1.77-6.39, p < 0.001), all-cause death or HF hospitalization (HR 2.49, 95% CI 1.53-4.04, p < 0.001) and cardiac death or HF hospitalization (HR 2.28, 95% CI 1.28-4.07, p = 0.005) compared with those in tertile 2 or 3. These findings were consistent after multivariable adjustment. CONCLUSIONS: Unintentional weight loss is associated with worse prognosis in patients with HFpEF and overweight or obesity, even as haemodynamics, exercise capacity, and gas exchange are not different from patients with stable or increasing weight. These data underline important and fundamental differences between therapeutic and unintended weight loss in HFpEF.
  • Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold.
    Shunichi Doi; Atsushi Tada; Tomonari Harada; Jwan A Naser; Tatsuro Ibe; Joshua R Smith; Yogesh N V Reddy; Barry A Borlaug
    European journal of heart failure, 2025年06月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Oxygen consumption at peak exercise is widely used to assess functional impairment in heart failure with preserved ejection fraction (HFpEF), but few patients exercise to this intensity in daily living. Alternative metrics that quantify submaximal fitness may provide more patient-centred evaluations, but the pathophysiology of submaximal exercise intolerance in HFpEF is unexplored. METHODS AND RESULTS: Patients with HFpEF underwent invasive haemodynamic cardiopulmonary exercise testing with blood lactate measurement during exercise to volitional fatigue. Lactate threshold (LT) was defined as the exercise workload at which arterial lactate exceeded >2.0 mmol/L, taken as a measure of submaximal fitness. Of patients with HFpEF (n = 286), 194 (68%) reached LT at a workload of 40 W or less (LT ≤40 W), while 92 (32%) reached a workload exceeding 40 W at LT (LT >40 W). As compared to LT >40 W, patients with LT ≤40 W were more likely to be female, anaemic, and had greater pulmonary vascular disease (all p < 0.01). During 20 W exercise, participants with LT ≤40 W had higher pulmonary artery pressure, biventricular filling pressures, minute ventilation and respiratory drive, higher perceived dyspnoea and fatigue ratings, greater arterial-venous oxygen content difference, despite similar cardiac output and oxygen delivery. At peak exercise, most of these differences were no longer apparent. Findings were replicated using non-invasively-measured workload at ventilatory threshold. CONCLUSIONS: Two-thirds of patients with HFpEF reach LT at workloads typical of activities of daily living. Patients with HFpEF and impaired submaximal fitness are more likely to be female, have greater pulmonary vascular disease and anaemia severity, and display greater haemodynamic, symptomatic, and ventilatory control abnormalities during low-level exercise, which are not apparent at maximal exertion. These findings have therapeutic implications and suggest a potentially important role for wider evaluation of submaximal fitness in addition to peak aerobic capacity.
  • Impact of Right Ventricular Reserve Function During Exercise on Aortic Valve Opening in Patients with Left Ventricular Assist Device.
    Sakae Takenaka; Takuma Sato; Toshiyuki Nagai; Atsushi Tada; Yuta Kobayashi; Sho Kazui; Yutaro Yasui; Takeshi Hamaya; Yuki Mori; Akinori Takahashi; Suguru Ishizaka; Takao Konishi; Taro Temma; Kiwamu Kamiya; Tomonori Ooka; Satoru Wakasa; Toshihisa Anzai
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025年05月31日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although aortic valve (AV) opening during exercise has fewer adverse events in patients with a left ventricular (LV) assist device (LVAD), factors associated with it remains unclear. We hypothesized that right ventricular (RV) reserve function is associated with the AV opening status. This study aimed to explore the hemodynamic parameters observed at rest and during maximal exercise and investigate the association between the RV reserve function and AV opening status in patients with an LVAD. METHODS: We prospectively examined 25 consecutive patients with an LVAD who underwent invasive exercise right heart catheterization with simultaneous echocardiography in the supine position. The AV opening status was assessed at rest and during exercise. The change in RV stroke work index (RVSWI) from rest to peak exercise (ΔRVSWI) was calculated to assess the RV reserve function. Patients were divided into three groups according to AV opening: AV opening both at rest and during exercise (n = 7), AV opening during exercise only (n = 8), and closed AV (n = 10). RESULTS: Patients with a closed AV had significantly lower ΔRVSWI and ΔRV dP/dt max than those with AV opening both at rest and during exercise and AV opening during exercise only, whereas changes in pulmonary artery wedge pressure and pulmonary vascular resistance were comparable across the groups. In a multivariable logistic regression analysis, ΔRVSWI was independently associated with AV opening even after adjustment for the change in LV ejection fraction from rest to peak exercise. During a median follow-up period of 743 (interquartile range, 483-1,037) days, the incidence of adverse events was higher in patients in the closed AV group than in those in the AV opening groups (p = 0.002). CONCLUSIONS: RV reserve function is associated with AV opening status in patients with an LVAD. CLINICAL TRIAL REGISTRATION: URL: https://www.umin.ac.jp/ctr/index.htm. Unique Identifier: UMIN000039001.
  • Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting
    Yogesh N.V. Reddy; Atsushi Tada; Masaru Obokata; Rickey E. Carter; David M. Kaye; M. Louis Handoko; Mads J. Andersen; Kavita Sharma; Ryan J. Tedford; Margaret M. Redfield; Barry A. Borlaug
    Circulation, 151, 14, 976, 989, Ovid Technologies (Wolters Kluwer Health), 2025年04月08日, [査読有り], [筆頭著者]
    研究論文(学術雑誌), BACKGROUND:

    Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.

    METHODS:

    Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Derived cut points were tested in 3 additional validation cohorts (cohorts 4–6) in whom HFpEF was diagnosed by resting catheterization only (n=260), previous hospitalization for heart failure (n=447), or exercise echocardiography (n=517), respectively.

    RESULTS:

    Current recommended rule-out NT-proBNP threshold <125 pg/mL had 82% sensitivity (95% CI, 77%–88%) with a body mass index (BMI) <35 kg/m 2 , decreasing to 67% (95% CI, 58%–77%) with a BMI ≥35 kg/m 2 . A lower rule-out NT-proBNP threshold <50 pg/mL displayed good sensitivity with a BMI <35 kg/m 2 (97% [95% CI, 95%–99%]), with a modest decline in sensitivity with a BMI ≥35 kg/m 2 (86% [95% CI, 79%–93%]); diagnostic thresholds were confirmed in validation cohorts 1 and 2 (91% [95% CI, 88%–95%] and 86% [95% CI, 80%–93%] with a BMI <35 kg/m 2 ; 80% [95% CI, 74%–87%] and 84% [95% CI, 74%–93%] with a BMI ≥35 kg/m 2 ). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%–72%). Rule-in NT-proBNP threshold ≥500 pg/mL had 85% specificity (95% CI, 78%–91%) with a BMI <35 kg/m 2 (87% [95% CI, 80%–94%] and 90% [95% CI, 81%–99%] in validation cohorts), with 100% specificity at a BMI ≥35 kg/m 2 (93% [95% CI, 81%–100%] and 100% in validation cohorts). With a BMI ≥35 kg/m 2 , lower rule-in thresholds (≥220 pg/mL) provided good specificity (88% [95% CI, 73%–100%]; 93% [95% CI, 81%–100%] and 100% in validation cohorts). Findings were consistent in validation cohorts 3 through 6 (sensitivity of <50 pg/mL, 93%–98%; specificity of ≥500 pg/mL, 82%–89%). NT-proBNP provided no incremental discrimination among patients with history of AF; ≥98% of patients with AF and dyspnea were found to have HFpEF in our cohorts.

    CONCLUSIONS:

    In patients with chronic unexplained dyspnea, current rule-in and rule-out NT-proBNP diagnostic thresholds lead to unacceptably high error rates, with important interactions by obesity and AF status. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF. Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF.
  • Prognostic Value of Reticulocyte Production Ability in Patients with Chronic Heart Failure.
    Motoki Nakao; Toshiyuki Nagai; Atsushi Tada; Taro Koya; Suguru Ishizaka; Yoshifumi Mizuguchi; Fusako George; Yoshiya Kato; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Junichi Matsumoto; Ko Motoi; Hiroshi Okamoto; Masaharu Machida; Takahiko Saito; Toshihisa Anzai
    The Canadian journal of cardiology, 2025年02月07日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Anemia is frequently observed and associated with mortality in patients with heart failure (HF). Although the quality of erythropoiesis is an intrinsic aspect of anemia's pathophysiology, its prognostic value in HF patients is unclear. METHODS: Between January 2020 and October 2023, 1,328 symptomatic patients with chronic HF from a multicenter registry were prospectively examined. The reticulocyte production ability was evaluated by calculating the reticulocyte production index (RPI) using reticulocyte counts and serum hematocrit level. Patients were divided into four groups based on the presence or absence of anemia and the median RPI. The primary outcome was a composite of all-cause death and hospitalization for worsening HF. RESULTS: During a median follow-up of 551 (interquartile range 321-712) days, the primary outcome occurred in 219 patients. The incidence of the primary outcome was high among patients in the anemia and higher RPI group (≥ 0.978) (P <0.001). Higher RPI was independently associated with a higher risk of the primary outcome, even after adjusting for prognostic covariates (adjusted HR 1.37; 95% CI 1.05-1.78). Erythrocyte counts were significantly higher in patients with higher RPI in the groups without anemia (P <0.001); however, no significant differences were observed between the groups with anemia (P = 0.923). Serum iron levels and transferrin saturation did not significantly differ between the RPI groups with or without anemia. CONCLUSIONS: Higher RPI, which may reflect impaired maturation or a shortened lifespan of erythrocytes, was associated with worse clinical outcomes in HF patients irrespective of iron status.
  • Prevalence, Incidence, and Outcomes of Diastolic Dysfunction in Isolated Tricuspid Regurgitation
    Jwan A. Naser; Tomonari Harada; Atsushi Tada; Shunichi Doi; Gal Tsaban; Sorin V. Pislaru; Vuyisile T. Nkomo; Christopher G. Scott; Austin M. Kennedy; Mackram F. Eleid; Yogesh N.V. Reddy; Grace Lin; Patricia A. Pellikka; Barry A. Borlaug
    JACC: Cardiovascular Imaging, 17, 12, 1411, 1424, Elsevier BV, 2024年12月, [査読有り]
    研究論文(学術雑誌)
  • Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
    Atsushi Tada; Daniel Burkhoff; Jwan A. Naser; Tomonari Harada; Bianca Pourmussa; Yogesh N.V. Reddy; Michael D. Jensen; Rickey E. Carter; Ryan T. Demmer; Jeffrey M. Testani; Julio A. Chirinos; Barry A. Borlaug
    Circulation, 150, 13, 997, 1009, Ovid Technologies (Wolters Kluwer Health), 2024年09月24日, [査読有り], [筆頭著者]
    研究論文(学術雑誌), BACKGROUND:

    Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF.

    METHODS:

    In this secondary analysis from the CAMEO-DAPA trial (Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial), 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model.

    RESULTS:

    There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], −18.8 mm Hg [95% CI, −33.9 to −3.7] P =0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m 2 [95% CI, 0.003–0.11] P =0.039) and aortic root characteristic impedance (ETD, −2.6 mm Hg/mL*sec [95% CI: −5.1 to −0.03] P =0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, −292 mm Hg [95% CI, −530 to −53] P =0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, −7.3% [95% CI, −13.3 to −1.3] P =0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, P =0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, P <0.001).

    CONCLUSIONS:

    In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF.

    REGISTRATION:

    URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04730947.
  • Differential impacts of self-care behavior on clinical outcomes in patients with and without recent heart failure hospitalization.
    Taro Koya; Toshiyuki Nagai; Atsushi Tada; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Fusako George; Shogo Imagawa; Yusuke Tokuda; Yoshiya Kato; Masashige Takahashi; Hiroto Sakai; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Hiroshi Okamoto; Toshihisa Anzai
    International journal of cardiology, 132452, 132452, 2024年08月14日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although clinical guidelines recommend self-care assessment for patients with chronic heart failure (CHF), its prognostic significance remains controversial. This study aimed to compare the prognostic significance of self-care behavior on mortality between patients with and without a history of recent hospitalization for heart failure (HF). METHODS: We analyzed consecutive 1907 CHF patients from a Japanese multicenter registry (January 2020-June 2023) using the 9-item European Heart Failure Self-care Behavior Scale (EHFScBS-9) at enrolment. Suboptimal self-care behavior was defined as a score < 70 on the EHFScBS-9. Patients were divided into recent (within 30 days post-discharge, n = 664) and no recent hospitalization for HF groups (n = 1263), respectively. The primary outcome was a composite of all-cause death and rehospitalization for HF. RESULTS: During a median follow-up period of 427 (interquartile range 273-630) days, the primary outcome occurred in 100 patients. Patients with suboptimal self-care behavior exhibited a higher incidence of the primary outcome in the recent hospitalization for HF group (p = 0.020) but not in the no recent hospitalization for HF group (P = 0.16). Multivariable regressions showed suboptimal self-care behavior was independently associated with the primary outcome in the recent hospitalization for HF group with a significant interaction (P = 0.029). CONCLUSION: In patients recently hospitalized for HF, but not in those without a recent hospitalization history for HF, suboptimal self-care behavior was associated with adverse events. This indicates the importance of self-care education for these patients.
  • Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction
    Atsushi Tada; Shunichi Doi; Tomonari Harada; Tatsuro Ibe; Jwan A. Naser; Matthew Amdahl; Yogesh N.V. Reddy; Barry A. Borlaug
    JACC: Heart Failure, 12, 7, 1257, 1269, Elsevier BV, 2024年07月, [査読有り], [筆頭著者]
    研究論文(学術雑誌)
  • Imaging and mechanisms of heart failure with preserved ejection fraction: a state-of-the-art review
    Tomonari Harada; Atsushi Tada; Barry A Borlaug
    European Heart Journal - Cardiovascular Imaging, 25, 11, 1475, 1490, Oxford University Press (OUP), 2024年06月24日, [査読有り], [招待有り]
    研究論文(学術雑誌), Abstract

    Understanding of the pathophysiology of heart failure with preserved ejection fraction (HFpEF) has advanced rapidly over the past two decades. Currently, HFpEF is recognized as a heterogeneous syndrome, and there is a growing movement towards developing personalized treatments based on phenotype-guided strategies. Left ventricular dysfunction is a fundamental pathophysiological abnormality in HFpEF; however, recent evidence also highlights significant roles for the atria, right ventricle, pericardium, and extracardiac contributors. Imaging plays a central role in characterizing these complex and highly integrated domains of pathophysiology. This review focuses on established evidence, recent insights, and the challenges that need to be addressed concerning the pathophysiology of HFpEF, with a focus on imaging-based evaluations and opportunities for further research.
  • Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
    Jwan A Naser; Atsushi Tada; Tomonari Harada; Yogesh N V Reddy; Rickey E Carter; Jeffrey M Testani; Michael D Jensen; Barry A Borlaug
    Circulation, 149, 25, 2026, 2028, 2024年06月18日, [査読有り], [国際誌]
  • Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation
    Tomonari Harada; Jwan A. Naser; Atsushi Tada; Shunichi Doi; Tatsuro Ibe; Sorin V. Pislaru; Mackram F. Eleid; Hidemi Sorimachi; Masaru Obokata; Yogesh N.V. Reddy; Barry A. Borlaug
    European Journal of Heart Failure, 26, 7, 1616, 1627, Wiley, 2024年06月04日, [査読有り]
    研究論文(学術雑誌), Aims

    This study aimed to evaluate the clinical significance of secondary mitral regurgitation (MR) in patients with heart failure with preserved ejection fraction (HFpEF).

    Methods and results

    We conducted a prospective study enrolling consecutively evaluated patients with HFpEF undergoing invasive haemodynamic exercise testing with simultaneous echocardiography. Compared to HFpEF without MR (n = 145, 79.7%), those with mild or moderate MR (n = 37, 20.3%) were older, more likely to be women, had more left ventricular (LV) systolic dysfunction, and more likely to have left atrial (LA) myopathy reflected by greater burden of atrial fibrillation, more LA dilatation, and poorer LA function. Pulmonary artery (PA) wedge pressure was higher at rest in HFpEF with MR (17 ± 5 mmHg vs. 20 ± 5 mmHg, p = 0.005), but there was no difference with exercise. At rest, only 2 (1.1%) patients had moderate MR, and none developed severe MR. Pulmonary vascular resistance was higher, and right ventricular (RV)‐PA coupling was more impaired in patients with HFpEF and MR at rest and exercise. LV and LA myocardial dysfunction remained more severe in patients with MR during stress compared to those without MR, characterized by greater LA dilatation during all stages of exertion, lower LA emptying fraction and compliance, steeper and rightward‐shifted LA pressure–volume relationships, and reduced LV longitudinal contractile function.

    Conclusions

    Patients with HFpEF and mild or moderate MR have more severe LV systolic dysfunction, LA myopathy, RV‐PA uncoupling, and more severe pulmonary vascular disease. Mitral valve incompetence in this setting is a phenotypic marker of more advanced disease but is not a causal factor in development of HFpEF.
  • Prognostic Value of Combined Assessments of Late Gadolinium Enhancement and Fluorodeoxyglucose Uptake in Cardiac Sarcoidosis
    Sho Kazui; Sakae Takenaka; Toshiyuki Nagai; Satonori Tsuneta; Kenji Hirata; Yoshiya Kato; Hirokazu Komoriyama; Yuta Kobayashi; Akinori Takahashi; Kiwamu Kamiya; Taro Temma; Takuma Sato; Atsushi Tada; Yutaro Yasui; Michikazu Nakai; Takahiro Sato; Ichizo Tsujino; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
    JACC: Cardiovascular Imaging, 17, 6, 710, 712, Elsevier BV, 2024年06月, [査読有り]
    研究論文(学術雑誌)
  • Is growth differentiation factor-15 a useful biomarker for chronic heart failure across body size?
    Atsushi Tada; Toshiyuki Nagai; Toshihisa Anzai
    International journal of cardiology, 132204, 132204, 2024年05月23日, [招待有り], [筆頭著者, 責任著者], [国際誌]
    英語
  • Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction
    Kathryn Larson; Massar Omar; Hidemi Sorimachi; Kazunori Omote; Alessio Alogna; Dejana Popovic; Atsushi Tada; Shunichi Doi; Jwan Naser; Yogesh N.V. Reddy; Margaret M. Redfield; Barry A. Borlaug
    European Journal of Heart Failure, 26, 3, 564, 577, Wiley, 2024年01月18日, [査読有り]
    研究論文(学術雑誌), Abstract

    Aims

    We aimed to clarify the extent to which cardiac and peripheral impairments to oxygen delivery and utilization contribute to exercise intolerance and risk for adverse events, and how this relates to diversity and multiplicity in pathophysiologic traits.

    Methods and results

    Individuals with heart failure with preserved ejection fraction (HFpEF) and non‐cardiac dyspnoea (controls) underwent invasive cardiopulmonary exercise testing and clinical follow‐up. Haemodynamics and oxygen transport responses were compared. HFpEF patients were then categorized a priori into previously‐proposed, non‐exclusive descriptive clinical trait phenogroups, including cardiometabolic, pulmonary vascular disease, left atrial myopathy, and vascular stiffening phenogroups based on clinical and haemodynamic profiles to contrast pathophysiology and clinical risk. Overall, patients with HFpEF (n = 643) had impaired cardiac output reserve with exercise (2.3 vs. 2.8 L/min, p = 0.025) and greater reliance on peripheral oxygen extraction augmentation (4.5 vs. 3.8 ml/dl, p < 0.001) compared to dyspnoeic controls (n = 219). Most (94%) patients with HFpEF met criteria for at least one clinical phenogroup, and 67% fulfilled criteria for multiple overlapping phenogroups. There was greater impairment in peripheral limitations in the cardiometabolic group and greater cardiac output limitations and higher pulmonary vascular resistance during exertion in the other phenogroups. Increasing trait multiplicity within a given patient was associated with worse exercise haemodynamics, poorer exercise capacity, lower cardiac output reserve, and greater risk for heart failure hospitalization or death (hazard ratio 1.74, 95% confidence interval 1.08–2.79 for 0–1 vs. ≥2 phenogroup traits present).

    Conclusions

    Though cardiac output response to exercise is limited in patients with HFpEF compared to those with non‐cardiac dyspnoea, the relative contributions of cardiac and peripheral limitations vary with differing numbers and types of clinical phenotypic traits present. Patients fulfilling criteria for greater multiplicity and diversity of HFpEF phenogroup traits have poorer exercise capacity, worsening haemodynamic perturbations, and greater risk for adverse outcome.
  • Exercise Capacity and Clinical Outcomes in Chronic Heart Failure Patients with Mild Tricuspid Regurgitation.
    Kosuke Nakamura; Suguru Ishizaka; Kazunori Omote; Yutaro Yasui; Yoshifumi Mizuguchi; Sakae Takenaka; Yui Shimono; Ko Motoi; Hiroyuki Aoyagi; Yoji Tamaki; Sho Kazui; Yuki Takahashi; Kohei Saiin; Seiichiro Naito; Atsushi Tada; Yuta Kobayashi; Takuma Sato; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    Journal of clinical medicine, 12, 23, 2023年12月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIM: The present study aimed to investigate the impact of mild tricuspid regurgitation (TR) on the exercise capacity or clinical outcomes in patients with chronic heart failure (CHF). METHODS AND RESULTS: The study enrolled 511 patients with CHF who underwent cardiopulmonary exercise testing (CPET) between 2013 and 2018. The primary outcome was a composite of heart failure hospitalization and death. Patients with mild TR (n = 324) or significant TR (moderate or greater; n = 60) displayed worse NHYA class and reduced exercise capacity on CPET than those with non-TR (n = 127), but these were more severely impaired in patients with significant TR. A total of 90 patients experienced events over a median follow-up period of 3.3 (interquartile range 0.8-5.5) years. Patients with significant TR displayed a higher risk of events, while patients with mild TR had a 3.0-fold higher risk of events than patients with non-TR (hazard ratio (HR) 3.01; 95% confidence interval (CI), 1.50-6.07). Multivariate Cox regression analysis showed that, compared with non-TR, mild TR was associated with increased adverse events, even after adjustment for co-variates (HR 2.97; 95% CI, 1.35-6.55). CONCLUSIONS: TR severity was associated with worse symptoms, reduced exercise capacity, and poor clinical outcomes. Even patients with mild TR had worse clinical characteristics than those with non-TR.
  • Differences in blood flow dynamics between balloon- and self-expandable valves in patients with aortic stenosis undergoing transcatheter aortic valve replacement.
    Yuki Takahashi; Kiwamu Kamiya; Toshiyuki Nagai; Satonori Tsuneta; Noriko Oyama-Manabe; Takeshi Hamaya; Sho Kazui; Yutaro Yasui; Kohei Saiin; Seiichiro Naito; Yoshifumi Mizuguchi; Sakae Takenaka; Atsushi Tada; Suguru Ishizaka; Yuta Kobayashi; Kazunori Omote; Takuma Sato; Yasushige Shingu; Kohsuke Kudo; Satoru Wakasa; Toshihisa Anzai
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 25, 1, 60, 60, 2023年10月26日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The differences in pre- and early post-procedural blood flow dynamics between the two major types of bioprosthetic valves, the balloon-expandable valve (BEV) and self-expandable valve (SEV), in patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR), have not been investigated. We aimed to investigate the differences in blood flow dynamics between the BEV and SEV using four-dimensional flow cardiovascular magnetic resonance (4D flow CMR). METHODS: We prospectively examined 98 consecutive patients with severe AS who underwent TAVR between May 2018 and November 2021 (58 BEV and 40 SEV) after excluding those without CMR because of a contraindication, inadequate imaging from the analyses, or patients' refusal. CMR was performed in all participants before (median interval, 22 [interquartile range (IQR) 4-39] days) and after (median interval, 6 [IQR 3-6] days) TAVR. We compared the changes in blood flow patterns, wall shear stress (WSS), and energy loss (EL) in the ascending aorta (AAo) between the BEV and SEV using 4D flow CMR. RESULTS: The absolute reductions in helical flow and flow eccentricity were significantly higher in the SEV group compared in the BEV group after TAVR (BEV: - 0.22 ± 0.86 vs. SEV: - 0.85 ± 0.80, P < 0.001 and BEV: - 0.11 ± 0.79 vs. SEV: - 0.50 ± 0.88, P = 0.037, respectively); there were no significant differences in vortical flow between the groups. The absolute reduction of average WSS was significantly higher in the SEV group compared to the BEV group after TAVR (BEV: - 0.6 [- 2.1 to 0.5] Pa vs. SEV: - 1.8 [- 3.5 to - 0.8] Pa, P = 0.006). The systolic EL in the AAo significantly decreased after TAVR in both the groups, while the absolute reduction was comparable between the groups. CONCLUSIONS: Helical flow, flow eccentricity, and average WSS in the AAo were significantly decreased after SEV implantation compared to BEV implantation, providing functional insights for valve selection in patients with AS undergoing TAVR. Our findings offer valuable insights into blood flow dynamics, aiding in the selection of valves for patients with AS undergoing TAVR. Further larger-scale studies are warranted to confirm the prognostic significance of hemodynamic changes in these patients.
  • 心臓サルコイドーシス患者の免疫抑制療法開始後における心筋トロポニン値経時的評価の予後的意義
    數井 翔; 竹中 秀; 永井 利幸; 加藤 喜哉; 小森山 弘和; 小林 雄太; 高橋 昌寛; 神谷 究; 佐藤 琢真; 多田 篤司; 安井 悠太郎; 中井 陸運; 佐藤 隆博; 辻野 一三; 今野 哲; 安斉 俊久
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 43, サプリメント号, 64, 64, 日本サルコイドーシス, 2023年10月
    日本語
  • Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis.
    Sho Kazui; Sakae Takenaka; Toshiyuki Nagai; Yoshiya Kato; Hirokazu Komoriyama; Yuta Kobayashi; Akinori Takahashi; Kiwamu Kamiya; Takuma Sato; Atsushi Tada; Yutaro Yasui; Michikazu Nakai; Takahiro Sato; Ichizo Tsujino; Satoshi Konno; Toshihisa Anzai
    International journal of cardiology, 389, 131268, 131268, 2023年08月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although high-sensitivity cardiac troponins may be sensitive and easily repeatable markers of disease activity in patients with cardiac sarcoidosis (CS), the association between longitudinal cardiac troponin trajectory and adverse events remains unclear. This study aimed to clarify whether longitudinal cardiac troponin levels were associated with adverse events in patients with CS. METHODS: We examined 63 consecutive CS-initiated prednisolone (PSL) patients with available longitudinal high-sensitivity cardiac troponin T (cTnT) data between December 2013 and March 2023. The area under the cTnT trajectory, which reflected cumulative cTnT release, was calculated to assess the association between longitudinal cTnT levels and adverse events. Patients were divided into two groups according to the median area under the cTnT trajectory per month. The primary outcome was a composite of sustained ventricular tachycardia or fibrillation, worsening heart failure, and sudden cardiac death (SCD). RESULTS: In total, 463 cTnT measurements were collected over a median follow-up period of 30.4 (interquartile range [IQR] 15.6-34.2) months. The primary outcome was observed in 12 (19%) patients. A higher area under the cTnT trajectory was significantly associated with an increased incidence of the primary outcome (P = 0.027), while cTnT levels before and one month after initiation of PSL, and these changes were not related to adverse events (P = 0.179, 0.096, and 0.95, respectively). CONCLUSIONS: Longitudinal cTnT trajectory following PSL initiation was associated with adverse cardiac events in patients with CS, suggesting that longitudinal measurement of cTnT would be useful for the early identification of high-risk patients.
  • JCS 2022 Guideline on Perioperative Cardiovascular Assessment and Management for Non-Cardiac Surgery.
    Eiji Hiraoka; Kengo Tanabe; Shinichiro Izuta; Tadao Kubota; Shun Kohsaka; Amane Kozuki; Kazuhiro Satomi; Hiroki Shiomi; Toshiro Shinke; Toshiyuki Nagai; Susumu Manabe; Yasuhide Mochizuki; Taku Inohara; Mitsuhiko Ota; Tetsuma Kawaji; Yutaka Kondo; Yumiko Shimada; Yohei Sotomi; Tomofumi Takaya; Atsushi Tada; Tomohiko Taniguchi; Kazuya Nagao; Kenichi Nakazono; Yukiko Nakano; Kazuhiko Nakayama; Yuichiro Matsuo; Takashi Miyamoto; Yoshinao Yazaki; Kazuyuki Yahagi; Takuya Yoshida; Kohei Wakabayashi; Hideki Ishii; Minoru Ono; Akihiro Kishida; Takeshi Kimura; Tetsuro Sakai; Yoshihiro Morino
    Circulation journal : official journal of the Japanese Circulation Society, 87, 9, 1253, 1337, 2023年08月10日, [査読有り], [招待有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Prognostic Value of Liver Fibrotic Markers in Patients With Heart Failure.
    Atsushi Tada; Toshiyuki Nagai; Yoshiya Kato; Noriko Oyama-Manabe; Satonori Tsuneta; Michikazu Nakai; Yutaro Yasui; Sho Kazui; Yuki Takahashi; Kohei Saiin; Seiichiro Naito; Sakae Takenaka; Yoshifumi Mizuguchi; Yuta Kobayashi; Suguru Ishizaka; Kazunori Omote; Takuma Sato; Takao Konishi; Kiwamu Kamiya; Kohsuke Kudo; Toshihisa Anzai
    The American journal of cardiology, 200, 115, 123, 2023年06月10日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Several liver fibrotic markers are associated with prognosis in patients with heart failure (HF). However, the optimal markers for outcome prediction remain unclear. This study aimed to simultaneously investigate the prognostic value of liver fibrotic markers and the associations between these markers and clinical parameters in patients with HF without organic liver disease. We prospectively examined 211 consecutive patients with chronic HF between April 2018 and August 2021, excluding those with organic liver disease, using liver magnetic resonance imaging and ultrasound. A total of 7 representative liver fibrotic markers were measured in all patients. The primary outcome of interest was the composite of all-cause death and hospitalization for worsening HF. During a median follow-up period of 747 (interquartile range 465 to 1,042) days, the primary outcome occurred in 45 patients. Patients with higher hyaluronic acid and type III procollagen N-terminal peptide (P-III-P) levels showed a significantly higher incidence of the primary outcome than those without (p <0.001 and p = 0.005, respectively). The multivariable Cox regression analysis revealed that hyaluronic acid and P-III-P levels were independently associated with the risk of adverse events (hazard ratio 1.84, 95% confidence interval 1.18 to 2.87 and hazard ratio 2.89, 95% confidence interval 1.32 to 6.34, respectively) even after adjustment for a mortality prediction model, whereas the other 5 markers were not associated with the primary outcome. In conclusion, among the representative liver fibrotic markers, hyaluronic acid and P-III-P might be the optimal markers for outcome prediction in patients with HF.
  • JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis.
    Toshiyuki Nagai; Takayuki Inomata; Takashi Kohno; Takuma Sato; Atsushi Tada; Toru Kubo; Kazufumi Nakamura; Noriko Oyama-Manabe; Yoshihiko Ikeda; Takeo Fujino; Yasuhide Asaumi; Takahiro Okumura; Toshiyuki Yano; Kazuko Tajiri; Hiroyuki Matsuura; Yuichi Baba; Haruki Sunami; Shingo Tsujinaga; Yasutoshi Ota; Keiko Ohta-Ogo; Yusuke Ishikawa; Hideo Matama; Nobutaka Nagano; Kimi Sato; Kazushi Yasuda; Yasushi Sakata; Koichiro Kuwahara; Tohru Minamino; Minoru Ono; Toshihisa Anzai
    Circulation journal : official journal of the Japanese Circulation Society, 87, 5, 674, 754, 2023年03月10日, [査読有り], [招待有り], [国内誌]
    英語, 研究論文(学術雑誌)
  • Impact of right ventricular reserve on exercise capacity and quality of life in patients with left ventricular assist device.
    Sakae Takenaka; Takuma Sato; Toshiyuki Nagai; Kazunori Omote; Yuta Kobayashi; Kiwamu Kamiya; Takao Konishi; Atsushi Tada; Yoshifumi Mizuguchi; Yuki Takahashi; Seiichiro Naito; Kohei Saiin; Suguru Ishizaka; Satoru Wakasa; Toshihisa Anzai
    American journal of physiology. Heart and circulatory physiology, 324, 3, H355-H363, 2023年03月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Although measuring right ventricular (RV) function during exercise is more informative than assessing it at rest, the relationship between RV reserve function, exercise capacity, and health-related quality of life (HRQoL) in patients with left ventricular assist devices (LVAD) remains unresolved. We aimed to investigate whether RV reserve assessed by the change in RV stroke work index (RVSWI) during exercise is correlated with exercise capacity and HRQoL in patients with LVAD. We prospectively assessed 24 consecutive patients with LVAD who underwent invasive right heart catheterization in the supine position. Exercise capacity and HRQoL were assessed using the 6-min walk distance (6 MWD) and peak oxygen consumption (V̇o2) in cardiopulmonary exercise testing, and the EuroQol visual analog scale (EQ-VAS), respectively. The patients were divided into two groups according to the median ΔRVSWI (change from rest to peak exercise). Patients with lower ΔRVSWI had significantly lower changes in cardiac index and absolute value of RV dP/dt than those with higher ΔRVSWI. The ΔRVSWI was positively correlated with 6 MWD (r = 0.59, P = 0.003) and peak V̇o2 (r = 0.56, P = 0.006). In addition, ΔRVSWI was positively correlated with the EQ-VAS (r = 0.44, P = 0.030). In contrast, there was no significant correlation between RVSWI at rest and 6 MWD (r = -0.34, P = 0.88), peak V̇o2 (r = 0.074, P = 0.74), or EQ-VAS (r = 0.127, P = 0.56). Our findings suggest that the assessment of RV reserve function is useful for risk stratification in patients with LVAD.NEW & NOTEWORTHY The change in right ventricular stroke work index (RVSWI) during exercise, not RVSWI at rest, was associated with exercise capacity and HRQoL. Our findings suggest that the assessment of change in RVSWI during exercise as a surrogate of RV reserve function may aid in risk stratification of patients with LVAD.
  • Prognostic Significance of Peak Workload-to-Weight Ratio by Cardiopulmonary Exercise Testing in Chronic Heart Failure.
    Yutaro Yasui; Kosuke Nakamura; Kazunori Omote; Suguru Ishizaka; Sakae Takenaka; Yoshifumi Mizuguchi; Yui Shimono; Sho Kazui; Yuki Takahashi; Kohei Saiin; Seiichiro Naito; Atsushi Tada; Yuta Kobayashi; Takuma Sato; Kiwamu Kamiya; Toshiyuki Nagai; Toshihisa Anzai
    The American journal of cardiology, 193, 37, 43, 2023年03月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The prognostic impact of peak workload-to-weight ratio (PWR) during cardiopulmonary exercise testing (CPET) and its determinants in patients with chronic heart failure (CHF) are not well understood. Consecutive 514 patients with CHF referred for CPET at the Hokkaido University Hospital between 2013 and 2018 were identified. The primary outcome was a composite of hospitalization because of worsening heart failure and death. PWR was calculated as peak workload normalized to body weight (W/kg) by CPET. Patients with low PWR (cut-off median 1.38 [W/kg], n = 257) were older and more anemic than those with high PWR (n = 257). In CPET, patients with low PWR displayed reduced peak oxygen consumption and impaired ventilatory efficiency compared with those with high PWR, whereas the peak respiratory exchange ratio was not significantly different between the 2 groups. There were 89 patients with events over a median follow-up period of 3.3 (interquartile range 0.8 to 5.5) years. The incidence of composite events was significantly higher in patients with low PWR than in those with high PWR (log-rank p <0.0001). In the multivariable Cox regression, lower PWR was associated with adverse events (hazard ratio 0.31, 95% confidence interval 0.13 to 0.73, p = 0.008). Low hemoglobin concentration was strongly related to impaired PWR (β coefficient = 0.43, per 1 g/100 ml increased, p <0.0001). In conclusion, PWR was associated with worse clinical outcomes, where blood hemoglobin was strongly related to PWR. Further study is required to identify therapies targeting peak workload achievements in exercise stress tests to improve the outcome in patients with CHF.
  • Association of coronary plaque morphology with inflammatory biomarkers and target lesion revascularization in patients with chronic coronary syndrome: an optical coherence tomography study.
    Kohei Saiin; Takao Konishi; Sho Kazui; Yutaro Yasui; Yuki Takahashi; Seiichiro Naito; Sakae Takenaka; Yoshifumi Mizuguchi; Atsushi Tada; Yuta Kobayashi; Yoshiya Kato; Kazunori Omote; Takuma Sato; Kiwamu Kamiya; Toshiyuki Nagai; Shinya Tanaka; Toshihisa Anzai
    American journal of cardiovascular disease, 13, 5, 309, 319, 2023年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The characteristics of high-risk coronary atherosclerosis evaluated using optical coherence tomography (OCT) can have a prognostic role. Inflammatory biomarkers may be related to the severity of coronary artery disease. This study investigated the association of high-risk morphological features of coronary plaques on OCT with circulating levels of inflammatory biomarkers and target lesion revascularization (TLR). MATERIALS AND METHODS: We prospectively analyzed the data of 30 consecutive patients with chronic coronary syndrome who underwent percutaneous coronary intervention (PCI) using OCT. The levels of interleukin-6, tumor necrosis factor-alpha, high-sensitivity C-reactive protein, pentraxin 3, vascular endothelial growth factor, and monocyte chemoattractant protein-1 (MCP-1) were measured in plasma samples. Coronary plaque characteristics were scored quantitatively in the form of coronary plaque risk score (CPRS). The estimated high-risk plaque characteristics for TLR were plaque rupture, plaque erosion, calcified nodule, lipid-rich plaque, thin-cap fibroatheroma, cholesterol crystals, macrophage infiltration, microchannels, calcification angle >90°, and microcalcifications. Each high-risk feature carries 1 point. Patients were defined as having a low CPRS (CPRS ≤3) or a high CPRS (CPRS ≥4). RESULTS: The primary outcome was TLR. TLR occurred in 6 (20%) patients within 15 months of PCI. High CPRS on OCT was directly correlated with TLR (P=0.029). In logistic regression analysis, CPRS was associated with TLR (odds ratio, 10.0; 95% confidence interval, 1.34-74.5). Serum MCP-1 level was significantly correlated with the CPRS (P=0.020). CONCLUSIONS: In patients with chronic coronary syndrome, CPRS may be a surrogate predictor of TLR. Serum MCP-1 may aid in the detection of high-risk coronary atherosclerosis.
  • Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure
    Atsushi Tada; Toshiyuki Nagai; Taro Koya; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Yoshiya Kato; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Toshihisa Anzai
    ESC Heart Failure, 10, 2, 985, 994, Wiley, 2022年12月10日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Liver stiffness assessed by magnetic resonance elastography predicts clinical outcomes in patients with heart failure and without chronic liver disease
    Atsushi Tada; Toshiyuki Nagai; Yoshiya Kato; Kazunori Omote; Noriko Oyama-Manabe; Satonori Tsuneta; Yusuke Kudo; Mutsumi Nishida; Michikazu Nakai; Yuki Takahashi; Kohei Saiin; Seiichiro Naito; Yuta Kobayashi; Sakae Takenaka; Yoshifumi Mizuguchi; Kiwamu Kamiya; Takao Konishi; Takuma Sato; Kohsuke Kudo; Toshihisa Anzai
    European Radiology, 33, 3, 2062, 2074, Springer Science and Business Media LLC, 2022年11月03日, [査読有り], [筆頭著者]
    研究論文(学術雑誌)
  • 日本人心臓サルコイドーシス患者におけるAHA/ACC/HRSガイドライン植込型除細動器適応の外的妥当性
    竹中 秀; 小林 雄太; 永井 利幸; 加藤 喜哉; 小森山 弘和; 永野 伸卓; 神谷 究; 小西 崇夫; 佐藤 琢真; 表 和徳; 多田 篤司; 水口 賢史; 草野 研吾; 植田 初江; 安斉 俊久
    日本サルコイドーシス/肉芽腫性疾患学会雑誌, 42, サプリメント号, 64, 64, 日本サルコイドーシス, 2022年10月
    日本語
  • Neoatherosclerosis with silent plaque rupture in a saphenous vein graft causing no re-flow phenomenon assessed by optical coherence tomography and histopathology.
    Takao Konishi; Yuki Takahashi; Sho Kazui; Yutaro Yasui; Kohei Saiin; Seiichiro Naito; Sakae Takenaka; Yoshifumi Mizuguchi; Atsushi Tada; Yuta Kobayashi; Kazunori Omote; Takuma Sato; Kiwamu Kamiya; Toshiyuki Nagai; Shinya Tanaka; Toshihisa Anzai
    Cardiology journal, 29, 4, 718, 719, 2022年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Vulnerable plaque derived from aspirated thrombi in recurrent acute coronary syndrome with familial hypercholesterolemia despite intensive lipid-lowering statin therapy.
    Hiroyuki Natsui; Takao Konishi; Kohei Saiin; Youji Tamaki; Tomoya Sato; Sakae Takenaka; Atsushi Tada; Yoshifumi Mizuguchi; Yuta Kobayashi; Takuma Sato; Rui Kamada; Kiwamu Kamiya; Toshiyuki Nagai; Shinya Tanaka; Toshihisa Anzai
    Cardiology Journal, 29, 2, 362, 363, 2022年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Performance of the H2FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry.
    Atsushi Tada; Toshiyuki Nagai; Kazunori Omote; Hiroyuki Iwano; Shingo Tsujinaga; Kiwamu Kamiya; Takao Konishi; Takuma Sato; Hirokazu Komoriyama; Yuta Kobayashi; Sakae Takenaka; Yoshifumi Mizuguchi; Tomoya Sato; Kazuhiro Yamamoto; Tsutomu Yoshikawa; Yoshihiko Saito; Toshihisa Anzai
    International journal of cardiology, 342, 43, 48, 2021年08月05日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Diagnosing heart failure with preserved ejection fraction (HFpEF) is challenging. Although the H2FPEF score and HFA-PEFF algorithm have been proposed for diagnosing HFpEF, previous validation studies were conducted in stable chronic heart failure (HF). Moreover, information on their applicability in the Asian population is limited. We sought to investigate these scores' diagnostic performance for HFpEF in Japanese patients recently hospitalized due to acute decompensated HF. METHODS: We examined patients with HFpEF recently hospitalized with acute decompensated HF from a nationwide HFpEF-specific multicenter registry (HFpEF group) and control patients who underwent echocardiography to investigate the cause of dyspnea in our hospital (Non-HFpEF group). RESULTS: The studied population included 372 patients (194 HFpEF group and 178 Non-HFpEF group; HFpEF prevalence, 52%). A high H2FPEF score (6-9 points) could diagnose HFpEF with a high specificity of 97% and a positive predictive value (PPV) of 94%, and a low H2FPEF score (0-1 point) could rule out HFpEF with a high sensitivity of 97% and a negative predictive value (NPV) of 93%. HFpEF could be diagnosed with a high HFA-PEFF score (5-6 points) (specificity, 84%; PPV, 82%) or ruled out with a low HFA-PEFF score (0-1 point) (sensitivity, 99%; NPV, 89%). The H2FPEF score was significantly superior to the HFA-PEFF score in diagnostic accuracy (area under the curve: 0.89 vs. 0.82, respectively, p = 0.004). CONCLUSIONS: The H2FPEF and the HFA-PEFF scores had acceptable diagnostic accuracy in diagnosing HFpEF in Japanese patients.
  • Applicability of the AHA/ACC/HRS Guideline for Implantable Cardioverter Defibrillator Implantation in Japanese Patients With Cardiac Sarcoidosis.
    Sakae Takenaka; Yuta Kobayashi; Toshiyuki Nagai; Yoshiya Kato; Hirokazu Komoriyama; Nobutaka Nagano; Kiwamu Kamiya; Takao Konishi; Takuma Sato; Kazunori Omote; Yoshifumi Mizuguchi; Atsushi Tada; Tomoya Sato; Hiroyuki Iwano; Kengo Kusano; Hatsue Ishibashi-Ueda; Toshihisa Anzai
    JACC. Clinical electrophysiology, 7, 11, 1410, 1418, 2021年06月22日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: This study aimed to assess, among Japanese patients with cardiac sarcoidosis (CS), the implantable cardioverter-defibrillator (ICD) recommendations from the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (SCD). BACKGROUND: Although ICDs are used to prevent SCD from ventricular tachycardia or ventricular fibrillation (VT/VF) in patients with CS, the generalizability of the AHA/ACC/HRS guidelines for Japanese patients with CS remains unclear. METHODS: This study examined 188 consecutive patients with CS in 2 tertiary hospitals between 1979 and 2020. Patients were followed for a primary outcome of VT/VF or SCD. RESULTS: During a median follow-up of 5.68 years, the primary outcome occurred in 44 patients (23%). Patients with a class I recommendation for ICD implantation showed the highest incidence of the primary outcome among patients in whom the guideline recommendations for ICD implantation were used (log-rank test; p = 0.03). However, compared with patients with left ventricular ejection fractions (LVEFs) ≤35%, there was no significant difference in the incidence of the primary outcome among patients with LVEFs >35% and those who required a permanent pacemaker (p = 0.31); similar results were observed in those with LVEFs >35% and late gadolinium enhancement during cardiovascular magnetic resonance imaging (p = 0.22). CONCLUSIONS: The American guideline recommendations for ICD implantation might be applicable to Japanese patients with CS. Implantation of an ICD may need to be considered in these patients if they require a permanent pacemaker or have late gadolinium enhancement, regardless of LVEF.
  • Different Prognostic Impact of the Morning Blood Pressure Surge in Heart Failure With Reduced vs. Preserved Ejection Fraction.
    Atsushi Tada; Hidemi Sorimachi; Kazunori Omote
    Circulation journal : official journal of the Japanese Circulation Society, 85, 9, 1543, 1544, 2021年05月18日, [査読有り], [招待有り], [筆頭著者], [国内誌]
    英語, 研究論文(学術雑誌)
  • Prognostic value of admission serum magnesium in acute myocardial infarction complicated by malignant ventricular arrhythmias.
    Yoshifumi Mizuguchi; Takao Konishi; Toshiyuki Nagai; Tomoya Sato; Sakae Takenaka; Atsushi Tada; Yuta Kobayashi; Hirokazu Komoriyama; Yoshiya Kato; Kazunori Omote; Takuma Sato; Kiwamu Kamiya; Shingo Tsujinaga; Hiroyuki Iwano; Kenjiro Kikuchi; Shinya Tanaka; Toshihisa Anzai
    The American journal of emergency medicine, 44, 100, 105, 2021年02月05日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: Although electrolyte abnormalities are related to worse clinical outcomes in patients with acute myocardial infarction (AMI), little is known about the association between admission serum magnesium level and adverse events in AMI patients complicated by out-of-hospital cardiac arrest presenting with malignant ventricular arrhythmias (OHCA-MVA). We investigated the prognostic value of serum magnesium level on admission in these patients. METHODS: We retrospectively analyzed the data of 165 consecutive reperfused AMI patients complicated with OHCA-MVA between April 2007 and February 2020 in our university hospital. Serum magnesium concentration was measured on admission. The primary outcome was in-hospital death. RESULTS: Fifty-four patients (33%) died during hospitalization. Higher serum magnesium level was significantly related to in-hospital death (Fine & Gray's test; p < 0.001). In multivariable logistic regression analyses, serum magnesium level on admission was independently associated with in-hospital death (hazard ratio 2.68, 95% confidence interval 1.24-5.80) even after adjustment for covariates. Furthermore, the incidences of cardiogenic shock necessitating an intra-aortic balloon pump (p = 0.005) or extracorporeal membrane oxygenation (p < 0.001), tracheal intubation (p < 0.001) and persistent vegetative state (p = 0.002) were significantly higher in patients with higher serum magnesium level than in those with lower serum magnesium level. CONCLUSIONS: In reperfused AMI patients complicated by OHCA-MVA, admission serum magnesium level might be a potential surrogate marker for predicting in-hospital death.
  • Acute Myocardial Infarction of the Left Main Coronary Artery Presenting with Cardiogenic Shock and Pulmonary Edema during Noncardiac Surgery.
    Sakae Takenaka; Takao Konishi; Tomoya Sato; Atsushi Tada; Takuya Koizumi; Yoshifumi Mizuguchi; Takahide Kadosaka; Ko Motoi; Yuta Kobayashi; Hirokazu Komoriyama; Yoshiya Kato; Miwa Sarashina; Kazunori Omote; Shingo Tsujinaga; Takuma Sato; Rui Kamada; Kiwamu Kamiya; Hiroyuki Iwano; Toshiyuki Nagai; Tatsuya Orimo; Hirofumi Kamachi; Akinobu Taketomi; Toshihisa Anzai
    Case reports in cardiology, 2021, 5460816, 5460816, 2021年, [査読有り], [国際誌]
    英語, Acute myocardial infarction (AMI) caused by severe stenosis of left main coronary artery (LMCA) presenting with cardiogenic shock and pulmonary edema during noncardiac surgery is uncommon, but a catastrophic event. A 77-year-old male with cholangiocarcinoma underwent hepatectomy. During the surgery, he presented with cardiogenic shock, which did not respond to infusion administration or vasopressor. A transesophageal echocardiogram revealed anterior, septal, and lateral severe hypokinesia and impaired left ventricular function. Emergent coronary angiogram showed severe stenosis of LMCA. The patient underwent primary percutaneous coronary intervention (PCI) under the support of intra-aortic balloon pump, followed by extracorporeal membrane oxygenation. The chest roentgenogram showed pulmonary edema. Two days after PCI, he successfully underwent hepatectomy and bile duct resection. Early identification of the cause of hemodynamic instability during noncardiac surgery and invasive strategy are important for minimizing the myocardial injury and improving clinical outcomes in AMI of LMCA.
  • The effectiveness of drug-coated balloons for two dissimilar calcific lesions assessed by near-infrared spectroscopy intravascular ultrasound and optical coherence tomography.
    Takao Konishi; Kohei Saiin; Youji Tamaki; Hiroyuki Natsui; Tomoya Sato; Sakae Takenaka; Atsushi Tada; Yoshifumi Mizuguchi; Yuta Kobayashi; Hirokazu Komoriyama; Yoshiya Kato; Takuma Sato; Rui Kamada; Kiwamu Kamiya; Toshiyuki Nagai; Shinya Tanaka; Toshihisa Anzai
    Cardiology journal, 28, 5, 794, 795, 2021年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Refractory Ventricular Tachycardia in a Patient With a Left Ventricular Assist Device Successfully Treated With Stellate Ganglion Phototherapy.
    Tomoya Sato; Rui Kamada; Takuya Koizumi; Sakae Takenaka; Atsushi Tada; Shingo Tsujinaga; Takao Konishi; Takuma Sato; Masaya Watanabe; Toshiyuki Nagai; Toshihisa Anzai
    The Canadian journal of cardiology, 36, 12, 1977.e1-1977.e3, 2020年12月, [査読有り], [国際誌]
    英語, Neuraxial modulation therapies, such as stellate ganglion block, thoracic epidural anaesthesia, and cardiac sympathetic denervation, are effective for ventricular arrhythmias. However, these treatments can increase the risk of bleeding and infection. In this case report, stellate ganglion phototherapy was safely and effectively performed for refractory ventricular tachycardias in a patient with a history of left ventricular assist device implantation. Stellate ganglion phototherapy may have the potential to treat refractory ventricular arrhythmias as an additive therapy or bridge therapy.
  • Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi.
    Shingo Tsujinaga; Hiroyuki Iwano; Tomohiro Oshino; Takahide Kadosaka; Yoshifumi Mizuguchi; Ko Motoi; Yasuyuki Chiba; Taro Koya; Taro Temma; Kiwamu Kamiya; Arata Fukushima; Takuya Koizumi; Tomoya Sato; Sakae Takenaka; Atsushi Tada; Suguru Ishizaka; Miwa Sarashina; Kazunori Omote; Rui Kamada; Takao Konishi; Takuma Sato; Toshiyuki Nagai; Hiroko Yamashita; Toshihisa Anzai
    Internal medicine (Tokyo, Japan), 59, 17, 2155, 2160, 2020年09月01日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
  • Prevalence, Determinants, and Prognostic Significance of Hospital Acquired Pneumonia in Patients with Acute Heart Failure.
    Atsushi Tada; Kazunori Omote; Toshiyuki Nagai; Yasuyuki Honda; Hiroki Nakano; Satoshi Honda; Naotsugu Iwakami; Yasuhiro Hamatani; Michikazu Nakai; Kunihiro Nishimura; Yasuhide Asaumi; Takeshi Aiba; Teruo Noguchi; Kengo Kusano; Hiroyuki Yokoyama; Satoshi Yasuda; Hisao Ogawa; Toshihisa Anzai
    Journal of clinical medicine, 9, 7, 2020年07月13日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), The prognostic impact of hospital-acquired pneumonia (HAP) in acute heart failure (AHF) patients have not been fully elucidated. We evaluated 776 consecutive hospitalized AHF patients. The primary in-hospital outcomes were all-cause death and worsening heart failure (WHF), while the outcome following discharge was all-cause death. The clinical diagnosis of HAP was based on clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Patients with HAP had a significantly higher incidence of in-hospital death (12% vs. 1%, p < 0.001), WHF during the hospitalization (28% vs. 7%, p < 0.001), and longer length of hospital stay (p = 0.003) than those without. Among patients who survived at discharge, during a median follow-up period of 741 (interquartile range 422-1000) days, the incidence of all-cause death was significantly higher in patients with HAP than in those without (p < 0.001). In the multivariable Cox regression, HAP development was independently associated with all-cause death after discharge (HR [hazard ratio] 1.86, 95%CI [confidence interval] 1.08-3.19). Furthermore, older age (OR [odds ratio] 1.04, 95%CI 1.01-1.08), male sex (OR 2.21, 95%CI 1.14-4.28), and higher serum white blood cell count (OR 1.18, 95%CI 1.09-1.29) and serum C-reactive protein (OR 1.08, 95%CI 1.01-1.06) were independently associated with HAP development. In hospitalized patients with AHF, HAP development was associated with worse clinical outcomes, suggesting the importance of prevention and early screening for HAP.
  • Emery-Dreifuss muscular dystrophy as a possible cause of coronary embolism.
    Atsushi Tada; Takao Konishi; Takuma Sato; Tomoya Sato; Takuya Koizumi; Sakae Takenaka; Yoshifumi Mizuguchi; Takahide Kadosaka; Ko Motoi; Yuta Kobayashi; Hirokazu Komoriyama; Yoshiya Kato; Kazunori Omote; Shingo Tsujinaga; Rui Kamada; Kiwamu Kamiya; Hiroyuki Iwano; Toshiyuki Nagai; Nanase Okazaki; Yoshihiro Matsuno; Toshihisa Anzai
    Cardiology journal, 27, 4, 443, 444, 2020年, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • 心臓サルコイドーシス患者におけるガドリニウム遅延造影心臓MRIとFDG-PETを用いた複合的画像評価の予後的意義
    數井 翔; 竹中 秀; 永井 利幸; 常田 慧徳; 加藤 喜哉; 小森山 弘和; 小林 雄太; 高橋 昌寛; 神谷 究; 天満 太郎; 佐藤 琢真; 多田 篤司; 安井 悠太郎; 中井 陸運; 佐藤 隆博; 辻野 一三; 工藤 與亮; 今野 哲; 安斉 俊久, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 43, サプリメント号, 65, 65, 2023年10月
    日本サルコイドーシス, 日本語
  • 【心不全/糖尿病パンデミック的現状とICU】心不全薬物治療の新展開
    多田 篤司; 安斉 俊久, ICUとCCU, 45, 8, 463, 470, 2021年08月
    医学図書出版(株), 日本語
■ 書籍等出版物
  • 医学のあゆみ 297巻6号『医療ビッグデータ・リアルワールドデータ研究のあり方・進め方』
    多田篤司; 安斉俊久, 臨床医学の観点からみた医療ビッグデータの定義・種類・利活用の実際
    医歯薬出版株式会社, 2026年05月, [分担執筆]
  • 24 −TWENTY FOUR− 戦う循環器当直医のための虎の巻
    多田篤司; 永井利幸, 1. 急性心筋炎の治療選択はどこでどのようにすればいい?
    メジカルビュー社, 2025年11月, [分担執筆]
  • 改訂第二版 腫瘍循環器診療ハンドブック
    日本腫瘍循環器学会編集委員会; 南博信, 癌治療関連心血管毒性(CTR-CVT)とは?
    メジカルビュー社, 2025年11月, 9784758319669, xv, 231p, 日本語, [分担執筆]
  • 血行動態ハンドブック Step by Stepで理解する体内循環
    永井, 利幸; 香坂, 俊, STEPⅡ 応用編 6 右室梗塞と左室梗塞(機械的合併症)
    メディカル・サイエンス・インターナショナル, 2024年05月07日, 4815730997, 208, 日本語, [分担執筆]
  • 最新の臨床WEB
    多田篤司, 慢性心不全(左室収縮率が保たれた心不全:HFmrEF/HFpEF)
    南江堂, 2024年04月, [分担執筆]
  • 内科診断学 第4版
    多田篤司、安斉俊久, 高血圧<症候・病態編>、高血圧<症例編>
    医学書院, 2024年03月, 9784260053150, [分担執筆]
  • 診断と治療 第111巻10号『心筋炎・心膜炎,感染性心内膜炎を診る,治す』
    多田篤司; 永井利幸, ◆心筋炎を診る,治す【心筋炎の分類,成因と症候】
    診断と治療社, 2023年10月, [分担執筆]
  • 心不全診療controversy
    多田篤司、永井利幸, 12 心臓サルコイドーシスでステロイドはどこまで減量するべきか,定期的な活動性評価でPET検査は必要か,バイオマーカーでもよいか?
    中外医学社, 2023年10月, 9784498136809, xi, 261p, 日本語, [分担執筆]
  • Heart View 2023年 9月号 『HFpEFをどう考えるか?』
    多田篤司; 安斉利久, HFpEFの病態における炎症の意義
    メディカルレビュー社, 2023年09月, [分担執筆]
  • 循環器内科 第92巻第3号『心腎連関の病態と治療 update』
    多田篤司; 安斉俊久, 心不全からみる心腎連関機序
    科学評論社, 2023年08月, [分担執筆]
  • 医学のあゆみ 285巻12号『HFpEF(左室駆出率が保たれた心不全)の病態と治療』
    多田篤司; 永井利幸, わが国におけるHFpEFの臨床的特徴と診断・治療に与える影響
    医歯薬出版株式会社, 2023年06月, [分担執筆]
  • Heart View 2023年 6月号 『心腎連関を再考する』
    多田篤司; 安斉俊久, 4. HFpEF を心腎連関から診る
    メディカルレビュー社, 2023年05月, [分担執筆]
  • 循環器ジャーナル Vol.71 No.2 『今だからこそ聞きたい心不全診療のこと。』
    多田篤司; 永井利幸, inflammatory DCMの心筋炎症は果たして治療標的になるのか?
    医学書院, 2023年04月, [分担執筆]
  • SGLT2阻害薬がもたらす心不全治療ストラテジーの変革
    多田篤司; 安斉俊久, 心不全の定義とステージ分類
    先端医学社, 2023年03月, [分担執筆]
  • Heart View 2023年 3月号 『二次性心筋症集中講座』
    多田篤司; 永井利幸, 識る 8. 心筋炎アップデート~疾患概念の整理と診療の課題
    メディカルレビュー社, 2023年03月, [分担執筆]
  • 月刊カレントテラピー Vol.41 No.2 『心筋炎 ―診断・治療の最新動向―』
    多田篤司, 急性心筋炎初期治療の基本手順
    ライフメディコム社, 2023年02月, [分担執筆]
  • 診断と治療 第110巻12号『日常診療でみる二次性心筋症・全身疾患関連の心障害』
    多田篤司; 永井利幸, ◆特定の原因による二次性心筋症(心筋障害) サルコイドーシス
    診断と治療社, 2022年12月, [分担執筆]
  • 循環器内科 第92巻第3号『心臓画像診断 Update』
    多田篤司; 永井利幸, 心不全における貧血・鉄欠乏の意義
    科学評論社, 2022年09月, [分担執筆]
  • Medical Practice 2022年9月号(39巻9号) 心不全パンデミックをどう乗り越えるか?
    多田篤司; 安斉俊久, ■治療/新しい心不全治療の考え方 2.新しい心不全薬をどう使うか? イバブラジン,SGLT2阻害薬,ベルイシグアト
    文光堂, 2022年08月, [分担執筆]
  • 循環器内科 第91巻第5号『新しい心不全薬のすべて』
    多田篤司; 安斉俊久, 【ARNIのすべて】ARNIを心不全患者にどのように使用するか?
    科学評論社, 2022年06月, [分担執筆]
  • 最新主要文献とガイドラインでみる 循環器内科学レビュー 2022-’23
    多田篤司; 永井利幸, 心臓サルコイドーシスの診断と治療
    総合医学社, 2021年11月24日, 488378746X, 413, [分担執筆]
  • ICUとCCU 2021年8月号
    多田篤司、安斉俊久, 心不全薬物治療の新展開
    医学図書出版株式会社, 2021年08月, [分担執筆]
  • Cardio-Coagulation Vol.8 No.4 2021.12
    多田篤司; 安斉俊久, From the world Conference ESC 2021
    メディカルレビュー社, 2021年06月, [分担執筆]
  • Heart View 2021年 1月『抗血小板・抗凝固薬投与の問題は解決した?』
    多田篤司; 永井利幸, 13.Expertise TAVI 後の抗血栓療法はどこまで進んだか?
    メジカルビュー社, 2020年12月09日, [分担執筆]
■ 講演・口頭発表等
  • Retinal Microvascular Imaging and Coronary Artery Disease: A Window Into Systemic Microcirculation
    Atsushi Tada; Takeshi Hamaya; Toshiyuki Nagai; Kanae Fukutsu; Michiyuki Saito; Kousuke Noda; Susumu Ishida; Toshihisa Anzai
    The 51st Annual Meeting of Japanese Society for Microcirculation, 2026年06月05日, 日本語, シンポジウム・ワークショップパネル(指名)
    2026年06月05日 - 2026年06月06日, [招待講演]
  • Natural history of exercise-induced left atrial hypertension in patients with heart failure and preserved ejection fraction
    Atsushi Tada; Jwan A. Naser; Shunichi Doi; Tomonari Harada; Tatsuro Ibe; Yogesh N.V. Reddy; d Barry A. Borlaug
    ESC congress 2025, 2025年08月31日, 英語, 口頭発表(一般)
    2025年08月29日 - 2025年09月01日
  • Relationship between pulmonary artery wedge pressure and left atrial pressure: pathophysiologic implications
    Atsushi Tada; Kazunori Omote; Ahmed U. Fayyaz; Trevor J. Simard; William R. Miranda; Jwan A. Naser; Yogesh N. V. Reddy; Margaret M. Redfield; d Barry A. Borlaug
    ESC congress 2025, 2025年08月31日, 英語, ポスター発表
    2025年08月29日 - 2025年09月01日
  • Pulmonary Vascular Resistance Distribution in Pulmonary Hypertension Associated with Left Heart Disease
    Atsushi Tada; Kazunori Omote; Ahmed Fayyaz; Yogesh N.V. Reddy; Katlyn E. Koepp; Andrew Rosenbaum; Atta Behfar; Robert P. Frantz; Margaret M. Redfield; Barry A. Borlaug
    American Heart Association's Scientific Sessions 2024, 2024年11月16日, 英語, ポスター発表
    2024年11月16日 - 2024年11月18日
  • Dapagliflozin Enhances Arterial and Venous Compliance during Exercise in Heart Failure with preserved Ejection Fraction
    Atsushi Tada; Daniel Burkhoff; Jwan; A. Naser; Tomonari Harada; Bianca Pourmussa; Yogesh N. V. Reddy; Michael D. Jensen; Rickey Carter; Jeffrey Testani; Julio A. Chirinos Barry A. Borlaug
    ESC congress 2024, 2024年08月31日, ポスター発表
    2024年08月30日 - 2024年09月02日
  • Primary Inflammatory Disease in Heart Failure with Preserved Ejection Fraction
    Atsushi Tada; Shunichi Doi; Tomonari; Harada; Tatsuro Ibe; Jwan; A. Naser; Matthew Amdahl Yogesh; N.V. Reddy; Barry A. Borlaug
    ESC congress 2024, 2024年08月31日, ポスター発表
    2024年08月30日 - 2024年09月02日
  • Applicability of the New Proposed Criteria for Iron Deficiency in Japanese Patients With Heart Failure
    Atsushi Tada; Toshiyuki Nagai; Taro Koya; Motoki Nakao; Suguru Ishizaka; Yoshifumi Mizuguchi; Hiroyuki Aoyagi; Shogo Imagawa; Yusuke Tokuda; Masashige Takahashi; Yoshiya Kato; Masaharu Machida; Kenichi Matsutani; Takahiko Saito; Toshihisa Anzai
    AHA’s Scientific Sessions 2023, 2023年11月07日, 英語, ポスター発表
    2023年11月05日 - 2023年11月07日
  • Prognostic Value of Liver Fibrotic Markers in Patients with Heart Failure
    Atsushi Tada; Toshiyuki Nagai; Yoshiya Kato; Yutaro Yasui; Sho Kazui; Yuki Takahashi; Kohei Saiin; Seiichiro Naito; Sakae Takenaka; Yoshifumi Mizuguchi; Yuta Kobayashi; Kazunori Omote; Takuma Sato; Kiwamu Kamiya; Toshihisa Anzai
    ESC congress 2023, 2023年08月25日, 英語, ポスター発表
    2023年08月25日 - 2023年08月28日
  • Usefulness of Liver Stiffness Assessed by Magnetic Resonance Elastography in Patients with Heart Failure
    Atsushi Tada; Toshiyuki Nagai; Yoshiya Kato; Toshihisa Anzai
    第87回日本循環器学会学術集会, 2023年03月10日, 英語, シンポジウム・ワークショップパネル(公募)
    2023年03月10日 - 2023年03月12日
  • 心不全患者における磁気共鳴エラストグラフィー法で測定された肝硬度の予後的意義
    多田篤司 永井 利幸 加藤 喜哉 表 和徳 真鍋 徳子 常田 慧徳 工藤 悠輔 西田 睦 小林 雄太 竹中 秀 水口 賢史 神谷 究 小西 崇夫 佐藤 琢真 安斉 俊久
    第26回日本心不全学会学術集会, 2022年10月21日, 英語, 口頭発表(一般)
    2022年10月21日 - 2022年10月23日
  • Prognostic Significance of Liver Stiffness Assessed by Magnetic Resonance Elastography in Patients with Heart Failure
    Tada A; Nagai T; Kato Y; Omote K; Takahashi Y; Saiin K; Naito S; Takenaka S; Mizuguchi Y; Kobayashi Y; Konishi T; Sato T; Kamiya K; Anzai T
    American College of Cardiology 2022, 2022年04月, 英語, ポスター発表
    2022年04月 - 2022年04月
  • Validation of the HFA-PEFF and the H2FPEF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicentre registry
    Tada A; Nagai T; Omote K; Iwano H; Tsujinaga S; Kamiya K; Konishi T; Sato T; Komoriyama H; Kobayashi Y; Takenaka S; Mizuguchi Y; Sato T; Yamamoto K; Yoshikawa T; Saito Y; Anzai T
    ESC congress 2021, 2021年08月, 英語, ポスター発表
    2021年08月27日 - 2021年08月30日
  • 当院における心不全患者に対する心臓リハビリテーションの現状
    多田 篤司、小野 太祐、森 博子、庄司 寛、斉藤 高彦
    第20回日本心不全学会学術集会, 2016年10月, 日本語, ポスター発表
  • 当院で複数回心肺運動負荷試験(CPX)を行った心不全患者の検討
    多田 篤司; 小野 太祐; 小森山 弘和; 松谷 健一; 徳原 教; 斉藤 高彦; 森 博子; 庄司 寛; 本間 傑
    第22回日本心臓リハビリテーション学会学術集会, 2016年07月, ポスター発表
■ 所属学協会
  • 日本心臓移植学会
  • 日本移植学会
  • 日本人工臓器学会
  • 日本心不全学会
  • 日本経カテーテル心臓弁治療学会
  • 日本心臓リハビリテーション学会
  • 日本心臓病学会
  • 日本心血管インターベンション治療学会
  • 日本循環器学会
  • 日本内科学会
■ 共同研究・競争的資金等の研究課題
  • 運動負荷血行動態解析による心臓アミロイドーシス早期診断法の開発
    科学研究費助成事業
    2026年04月 - 2029年03月
    多田 篤司
    日本学術振興会, 若手研究, 北海道大学, 研究代表者, 26K19205
  • 深層学習を用いた眼底画像の解析による冠動脈疾患の検出
    科学研究費助成事業 研究活動スタート支援
    2022年08月 - 2024年03月
    多田 篤司
    日本学術振興会, 研究活動スタート支援, 北海道大学, 研究代表者, 22K20875
  • 運動負荷右心カテーテル検査を用いた心筋症の早期診断と病態解明
    第36回伊藤記念研究助成
    多田篤司
    一般社団法人北海道心臓協会, 北海道大学 循環器内科学教室, 研究代表者
  • 左房機能に着目したHFpEFの病態解明
    2022年度 ポストドクトラルフェローシップⅠ
    多田篤司
    公益財団法人 上原記念生命科学財団, 研究代表者
■ 学術・社会貢献活動/その他
社会貢献活動
  • 心筋症医療のいま~診断から治療、生活まで~
    2025年11月15日
    講師
    一般財団法人 北海道難病連
    札幌市難病医療相談会「特発性拡張型心筋症・肥大型心筋症」